

# Live Attenuated versus Inactivated Influenza Vaccine in

New England Journal of Medicine

356, 685-696

DOI: [10.1056/nejmoa065368](https://doi.org/10.1056/nejmoa065368)

Citation Report

#	ARTICLE	IF	CITATIONS
2	The role of oseltamivir in the treatment and prevention of influenza in children. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 755-767.	1.5	25
3	Needle-free vaccine delivery. Expert Opinion on Drug Delivery, 2007, 4, 459-474.	2.4	54
5	Inactivated and Live Attenuated Influenza Vaccines in Young Children – How Do They Compare?. New England Journal of Medicine, 2007, 356, 729-731.	13.9	17
6	Comparative Immunogenicities of Frozen and Refrigerated Formulations of Live Attenuated Influenza Vaccine in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 2007, 51, 4001-4008.	1.4	31
7	Efficacy and Safety of a Live Attenuated, Cold-Adapted Influenza Vaccine, Trivalent Against Culture-Confirmed Influenza in Young Children in Asia. Pediatric Infectious Disease Journal, 2007, 26, 619-628.	1.1	174
8	Immunizations, neonatal hyperbilirubinemia and animal-induced injuries. Current Opinion in Pediatrics, 2007, 19, 492-502.	1.0	0
10	Prospects for Prevention of Otitis Media. Pediatric Infectious Disease Journal, 2007, 26, S20-S22.	1.1	5
11	Influenza vaccine: The challenge of antigenic drift. Vaccine, 2007, 25, 6852-6862.	1.7	568
12	Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending day-care centres. Vaccine, 2007, 25, 8010-8020.	1.7	27
13	Toxicological evaluation of live attenuated, cold-adapted H5N1 vaccines in ferrets. Vaccine, 2007, 25, 8664-8672.	1.7	25
14	Evolution, Benefits, and Shortcomings of Vaccine Management. Journal of Managed Care Pharmacy, 2007, 13, 2-6.	2.2	8
15	Recent Publications on Medications and Pharmacy. Hospital Pharmacy, 2007, 42, 481-487.	0.4	0
16	Bridging the knowledge gaps in vaccine design. Nature Biotechnology, 2007, 25, 1361-1366.	9.4	168
17	Translational Research on Vaccines: Influenza as an Example. Clinical Pharmacology and Therapeutics, 2007, 82, 745-749.	2.3	14
18	Vergelijking van de werkzaamheid van vaccinatie van kinderen met levend verzwakt influenzavirus en geïnactiveerd (dood) influenzavirus. Medisch-farmaceutische Mededelingen, 2007, 45, 234-235.	0.0	0
19	The threat of avian influenza A (H5N1). Part IV: development of vaccines. Medical Microbiology and Immunology, 2007, 196, 213-225.	2.6	40
20	REVIEW ARTICLE: Secreted Heat Shock Protein gp96: An Innovative Vaccine Approach. American Journal of Reproductive Immunology, 2008, 59, 407-416.	1.2	26
21	Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza and Other Respiratory Viruses, 2008, 2, 193-202.	1.5	99

#	ARTICLE	IF	CITATIONS
22	Immunization with live influenza viruses in an experimental model of allergic bronchial asthma: infection and vaccination. <i>Influenza and Other Respiratory Viruses</i> , 2008, 2, 165-174.	1.5	5
23	Update on influenza vaccines. <i>Respirology</i> , 2008, 13, S41-S43.	1.3	8
24	Molecular studies of temperature-sensitive replication of the cold-adapted B/Ann Arbor/1/66, the master donor virus for live attenuated influenza FluMist® vaccines. <i>Virology</i> , 2008, 380, 354-362.	1.1	29
25	Influenza vaccines and vaccination strategies in birds. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2008, 31, 121-165.	0.7	82
26	Innate sensors of influenza virus: clues to developing better intranasal vaccines. <i>Expert Review of Vaccines</i> , 2008, 7, 1435-1445.	2.0	36
27	New vaccines for children. <i>Paediatrics and Child Health (United Kingdom)</i> , 2008, 18, 491-495.	0.2	0
28	Immunological commonalities and distinctions between airway and digestive immunity. <i>Trends in Immunology</i> , 2008, 29, 505-513.	2.9	112
29	Parent-collected respiratory specimens—A novel method for respiratory virus and vaccine efficacy research. <i>Vaccine</i> , 2008, 26, 1826-1831.	1.7	35
30	Safety evaluation of pulmonary influenza vaccination in healthy and “asthmatic” mice. <i>Vaccine</i> , 2008, 26, 2360-2368.	1.7	8
32	Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United States. <i>Vaccine</i> , 2008, 26, 2841-2848.	1.7	53
33	Report of the 4th meeting on the “Evaluation of pandemic influenza prototype vaccines in clinical trials”. <i>Vaccine</i> , 2008, 26, 4975-4977.	1.7	4
34	Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. <i>Vaccine</i> , 2008, 26, 4210-4217.	1.7	84
35	Seasonal inactivated influenza virus vaccines. <i>Vaccine</i> , 2008, 26, D5-D9.	1.7	89
36	Safety and efficacy of live attenuated influenza vaccine in children 2–7 years of age. <i>Vaccine</i> , 2008, 26, D10-D16.	1.7	94
37	Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5–49 years of age. <i>Vaccine</i> , 2008, 26, 4940-4946.	1.7	92
38	New vaccine approaches for seasonal and pandemic influenza. <i>Vaccine</i> , 2008, 26, 6232-6236.	1.7	19
39	Efficacy and effectiveness of influenza vaccination. <i>Vaccine</i> , 2008, 26, D17-D22.	1.7	103
40	Mucosal vaccination against bacterial respiratory infections. <i>Expert Review of Vaccines</i> , 2008, 7, 1257-1276.	2.0	31

#	ARTICLE	IF	CITATIONS
41	Flu Myths: Dispelling the Myths Associated With Live Attenuated Influenza Vaccine. Mayo Clinic Proceedings, 2008, 83, 77-84.	1.4	45
42	Availability of Trivalent Inactivated Influenza Vaccine to Parents of Neonatal Intensive Care Unit Patients and Its Effect on the Healthcare Worker Vaccination Rate. Infection Control and Hospital Epidemiology, 2008, 29, 309-313.	1.0	15
43	Update on antivirals and vaccines for seasonal and potential pandemic use. Expert Review of Respiratory Medicine, 2008, 2, 391-402.	1.0	0
44	Vaccines against epidemic and pandemic influenza. Expert Opinion on Drug Delivery, 2008, 5, 1139-1157.	2.4	29
45	A case for immunization against nosocomial infections. Journal of Leukocyte Biology, 2008, 83, 483-488.	1.5	11
46	Safety and Immunogenicity of Concurrent Administration of Live Attenuated Influenza Vaccine With Measles-Mumps-Rubella and Varicella Vaccines to Infants 12 to 15 Months of Age. Pediatrics, 2008, 121, 508-516.	1.0	40
47	Safety and Tolerability of Cold-Adapted Influenza Vaccine, Trivalent, in Infants Younger Than 6 Months of Age. Pediatrics, 2008, 121, e568-e573.	1.0	15
48	Adverse events associated with intranasal influenza vaccine in the United States. Therapeutic Advances in Respiratory Disease, 2008, 2, 193-198.	1.0	15
49	Differential Recruitment of Dendritic Cells and Monocytes to Respiratory Mucosal Sites in Children with Influenza Virus or Respiratory Syncytial Virus Infection. Journal of Infectious Diseases, 2008, 198, 1667-1676.	1.9	91
50	A call to cellular & humoral arms: Enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A. Hum Vaccin, 2008, 4, 148-157.	2.4	42
51	Estimating Influenza Vaccine Efficacy From Challenge and Community-based Study Data. American Journal of Epidemiology, 2008, 168, 1343-1352.	1.6	77
52	Emerging Data on the Safety and Efficacy of Influenza Vaccines in Children. Pediatric Infectious Disease Journal, 2008, 27, S159-S161.	1.1	20
53	Universal Influenza Vaccination and Live Attenuated Influenza Vaccination of Children. Pediatric Infectious Disease Journal, 2008, 27, S104-S109.	1.1	29
54	Prevention of Symptomatic Seasonal Influenza in 2005-2006 by Inactivated and Live Attenuated Vaccines. Journal of Infectious Diseases, 2008, 198, 312-317.	1.9	112
55	Phenotypic Changes in Influenza-Specific CD8 <sup>+</sup> T Cells after Immunization of Children and Adults with Influenza Vaccines. Journal of Infectious Diseases, 2008, 197, 803-811.	1.9	49
56	Development of a Vaccine Against Pandemic Influenza Viruses: Current Status and Perspectives. International Reviews of Immunology, 2008, 27, 392-426.	1.5	13
57	Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children. Vaccine Journal, 2008, 15, 1042-1053.	3.2	232
58	Influenza Virus and Acute Asthma in Children: In Reply. Pediatrics, 2008, 121, 1080-1080.	1.0	0

#	ARTICLE	IF	CITATIONS
59	Prevention of Influenza: Recommendations for Influenza Immunization of Children, 2007-2008. <i>Pediatrics</i> , 2008, 121, e1016-e1031.	1.0	48
60	Asthma prevalence and exacerbations in children: is there an association with childhood vaccination?. <i>Expert Review of Clinical Immunology</i> , 2008, 4, 687-694.	1.3	0
61	Influenza Vaccine Effectiveness Among Children 6 to 59 Months of Age During 2 Influenza Seasons. <i>JAMA Pediatrics</i> , 2008, 162, 943.	3.6	81
62	Monitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience. <i>Expert Review of Vaccines</i> , 2008, 7, 75-82.	2.0	23
63	Vaccines for preventing influenza in people with asthma. , 2008, , CD000364.		37
64	Influenza Virus and Acute Asthma in Children. <i>Pediatrics</i> , 2008, 121, 1079-1080.	1.0	6
65	Safety of the Intranasal, Trivalent, Live Attenuated Influenza Vaccine (LAIV) in Children With Intermittent Wheezing in an Open-Label Field Trial. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 444-452.	1.1	42
66	Modifying Clinical Practices to Manage Influenza in Children Effectively. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 738-743.	1.1	11
67	Update on universal childhood immunizations. <i>Current Opinion in Pediatrics</i> , 2008, 20, 483-489.	1.0	8
69	Antibody Responses After Inactivated Influenza Vaccine in Young Children. <i>Pediatric Infectious Disease Journal</i> , 2008, 27, 1004-1008.	1.1	27
70	Bench and bedside advances in otitis media. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2008, 16, 543-547.	0.8	5
71	Baseline Levels of Influenza-Specific CD4 Memory T-Cells Affect T-Cell Responses to Influenza Vaccines. <i>PLoS ONE</i> , 2008, 3, e2574.	1.1	48
72	Alternative vaccine delivery methods. , 2008, , 1357-1392.		10
73	Efectividad de la vacuna contra influenza: metanálisis de literatura. <i>Biomedica</i> , 2009, 29, 87.	0.3	9
75	Evaluation of Recombinant Influenza Virus-Simian Immunodeficiency Virus Vaccines in Macaques. <i>Journal of Virology</i> , 2009, 83, 7619-7628.	1.5	31
76	The Burden of Influenza in Children: Time for Prevention. <i>Clinical Infectious Diseases</i> , 2009, 49, 1022-1024.	2.9	3
77	Strategies for Pandemic and Seasonal Influenza Vaccination of Schoolchildren in the United States. <i>American Journal of Epidemiology</i> , 2009, 170, 679-686.	1.6	135
78	Update on vaccination guidelines for allergic children. <i>Expert Review of Vaccines</i> , 2009, 8, 1541-1546.	2.0	12

#	ARTICLE	IF	CITATIONS
79	Seasonal influenza vaccines: evolutions and future trends. <i>Expert Review of Vaccines</i> , 2009, 8, 383-389.	2.0	21
80	Blocking Interhost Transmission of Influenza Virus by Vaccination in the Guinea Pig Model. <i>Journal of Virology</i> , 2009, 83, 2803-2818.	1.5	79
81	Hot Topics in Infection and Immunity in Children V. <i>Advances in Experimental Medicine and Biology</i> , 2009, , .	0.8	1
82	Live Attenuated or Inactivated Influenza Vaccines and Medical Encounters for Respiratory Illnesses Among US Military Personnel. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 945.	3.8	80
83	Efficacy and Safety of 1 and 2 Doses of Live Attenuated Influenza Vaccine in Vaccine-Naive Children. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 365-371.	1.1	108
84	Influenza Vaccination with a Live Attenuated Vaccine. <i>American Journal of Nursing</i> , 2009, 109, 44-48.	0.2	2
85	Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines. <i>Expert Review of Vaccines</i> , 2009, 8, 469-481.	2.0	36
86	Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. <i>Hum Vaccin</i> , 2009, 5, 126-135.	2.4	41
87	The Risk of Seasonal and Pandemic Influenza: Prospects for Control. <i>Clinical Infectious Diseases</i> , 2009, 48, S20-S25.	2.9	49
88	Immunogenicity and Protective Efficacy of a Live Attenuated H5N1 Vaccine in Nonhuman Primates. <i>PLoS Pathogens</i> , 2009, 5, e1000409.	2.1	55
89	Seasonal Influenza: An Overview. <i>Journal of School Nursing</i> , 2009, 25, 4S-12S.	0.9	9
90	A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials. <i>BMC Pediatrics</i> , 2009, 9, 77.	0.7	20
91	Physicochemical and Immunological Characterization of N,N,N-Trimethyl Chitosan-Coated Whole Inactivated Influenza Virus Vaccine for Intranasal Administration. <i>Pharmaceutical Research</i> , 2009, 26, 1353-1364.	1.7	51
92	An update on swine-origin influenza virus A/H1N1: a review. <i>Virus Genes</i> , 2009, 39, 279-292.	0.7	123
93	Emergence and pandemic potential of swine-origin H1N1 influenza virus. <i>Nature</i> , 2009, 459, 931-939.	13.7	1,327
94	Outpatient management of asthma in children age 5-11 years: Guidelines for practice. <i>Journal of the American Academy of Nurse Practitioners</i> , 2009, 21, 261-269.	1.4	7
95	Vaccines: the Fourth Century. <i>Vaccine Journal</i> , 2009, 16, 1709-1719.	3.2	205
96	Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. <i>Vaccine</i> , 2009, 27, 530-541.	1.7	90

#	ARTICLE	IF	CITATIONS
97	Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. <i>Vaccine</i> , 2009, 27, 1101-1110.	1.7	167
98	Evidence of effectiveness from a large county-wide school-based influenza immunization campaign. <i>Vaccine</i> , 2009, 27, 2633-2636.	1.7	16
99	A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. <i>Vaccine</i> , 2009, 27, 3744-3753.	1.7	87
100	Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members. <i>Vaccine</i> , 2009, 27, 3568-3575.	1.7	43
101	Influenza control in the 21st century: Optimizing protection of older adults. <i>Vaccine</i> , 2009, 27, 5043-5053.	1.7	111
102	A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. <i>Vaccine</i> , 2009, 27, 5472-5479.	1.7	25
103	Kinetics of viral shedding and immune responses in adults following administration of cold-adapted influenza vaccine. <i>Vaccine</i> , 2009, 27, 7359-7366.	1.7	26
104	Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. <i>Vaccine</i> , 2009, 28, 228-234.	1.7	81
105	Efficacy of LAIV-T on Absentee Rates in a School-Based Health Center Sample. <i>Journal of Adolescent Health</i> , 2009, 45, 91-94.	1.2	33
106	Mucosal vaccines: novel advances in technology and delivery. <i>Expert Review of Vaccines</i> , 2009, 8, 1083-1097.	2.0	94
107	The Evolution of Influenza Resistance and Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1066.	3.8	86
109	Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. <i>Vaccine</i> , 2009, 27, 4953-4960.	1.7	109
110	Delivery systems: a vaccine strategy for overcoming mucosal tolerance?. <i>Expert Review of Vaccines</i> , 2009, 8, 103-112.	2.0	57
111	Influenza vaccination of children. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 720-721.	4.6	9
113	Update on universal annual influenza immunization recommendations for children. <i>Current Opinion in Pediatrics</i> , 2009, 21, 122-126.	1.0	10
115	Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 563-571.	1.1	185
118	Making improvements in influenza vaccines: incremental change or transformational evolution?. <i>Future Virology</i> , 2009, 4, 133-141.	0.9	0
119	Systematic Review: Safety and Efficacy of Extended-Duration Antiviral Chemoprophylaxis Against Pandemic and Seasonal Influenza. <i>Annals of Internal Medicine</i> , 2009, 151, 464.	2.0	42

#	ARTICLE	IF	CITATIONS
120	Peptide mimics of a conserved H5N1 avian influenza virus neutralization site. <i>Biochemical Journal</i> , 2009, 419, 133-139.	1.7	6
121	Anti-Influenza Serum and Mucosal Antibody Responses After Administration of Live Attenuated or Inactivated Influenza Vaccines to HIV-Infected Children. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 189-196.	0.9	41
123	The Efficacy of Live Attenuated and Inactivated Influenza Vaccines in Children as a Function of Time Postvaccination. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 806-811.	1.1	53
124	Optimizing Protection Against Influenza in Children Eligible for the Vaccine for Children Program. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 910-914.	1.1	6
125	Influenza: a unique problem in vaccination. <i>Future Virology</i> , 2010, 5, 651-664.	0.9	2
126	Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine. <i>Journal of Controlled Release</i> , 2010, 144, 17-24.	4.8	61
127	Breastfeeding is associated with the production of type I interferon in infants infected with influenza virus. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2010, 99, 1517-1521.	0.7	32
128	Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for influenza vaccination in children. <i>BMC Infectious Diseases</i> , 2010, 10, 168.	1.3	39
129	Influenza vaccines provide diminished protection but are cost-saving in older adults. <i>Journal of Internal Medicine</i> , 2010, 267, 220-227.	2.7	35
130	Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. <i>Influenza and Other Respiratory Viruses</i> , 2010, 4, 141-145.	1.5	47
131	The Population Impact of a Large School-Based Influenza Vaccination Campaign. <i>PLoS ONE</i> , 2010, 5, e15097.	1.1	26
132	A Paradigm for the Control of Influenza. <i>Journal of Infectious Diseases</i> , 2010, 202, 1619-1622.	1.9	4
133	Generation of Live Attenuated Novel Influenza Virus A/California/7/09 (H1N1) Vaccines with High Yield in Embryonated Chicken Eggs. <i>Journal of Virology</i> , 2010, 84, 44-51.	1.5	130
134	<i>In Vitro</i> Analysis of Virus Particle Subpopulations in Candidate Live-Attenuated Influenza Vaccines Distinguishes Effective from Ineffective Vaccines. <i>Journal of Virology</i> , 2010, 84, 10974-10981.	1.5	21
135	Influenza Vaccination of Children and Infection Rates in the Community—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 2355.	3.8	1
136	A 29-Year-Old Woman With Flu-like Symptoms. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 671.	3.8	4
137	Influenza Vaccination of Children and Infection Rates in the Community. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 2355.	3.8	4
138	Implementing a Community-Supported School-Based Influenza Immunization Program. <i>Biosecurity and Bioterrorism</i> , 2010, 8, 331-341.	1.2	19



#	ARTICLE	IF	CITATIONS
139	T Cell Responses of HIV-Infected Children after Administration of Inactivated or Live Attenuated Influenza Vaccines. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 51-59.	0.5	10
140	Avian influenza pandemic preparedness: developing pre-pandemic and pandemic vaccines against a moving target. <i>Expert Reviews in Molecular Medicine</i> , 2010, 12, e14.	1.6	23
141	Essential genes from Arctic bacteria used to construct stable, temperature-sensitive bacterial vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13456-13460.	3.3	49
142	Direct and Indirect Effectiveness of Influenza Vaccination Delivered to Children at School Preceding an Epidemic Caused by 3 New Influenza Virus Variants. <i>Journal of Infectious Diseases</i> , 2010, 202, 1626-1633.	1.9	80
143	Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza. <i>Expert Review of Respiratory Medicine</i> , 2010, 4, 171-177.	1.0	19
144	MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. <i>Expert Opinion on Biological Therapy</i> , 2010, 10, 639-651.	1.4	59
145	Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. <i>BMJ: British Medical Journal</i> , 2010, 340, c2649-c2649.	2.4	152
147	Vaccine effectiveness against laboratory-confirmed influenza in infants: A matched case control study. <i>Hum Vaccin</i> , 2010, 6, 729-735.	2.4	16
148	Update in Asthma 2009. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 1181-1187.	2.5	26
149	A substantial and confusing variation exists in handling of baseline covariates in randomized controlled trials: a review of trials published in leading medical journals. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 142-153.	2.4	132
150	Systemic, nasal and oral live vaccines against <i>Pseudomonas aeruginosa</i> : A clinical trial of immunogenicity in lower airways of human volunteers. <i>Vaccine</i> , 2010, 28, 707-713.	1.7	51
151	Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. <i>Vaccine</i> , 2010, 28, 1566-1574.	1.7	58
152	Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. <i>Vaccine</i> , 2010, 28, 2149-2156.	1.7	129
153	A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children. <i>Vaccine</i> , 2010, 28, 2865-2876.	1.7	57
154	Genetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine. <i>Vaccine</i> , 2010, 28, 5128-5134.	1.7	5
155	Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: In vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. <i>Vaccine</i> , 2010, 28, 3848-3855.	1.7	48
156	A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months. <i>Vaccine</i> , 2010, 28, 6137-6144.	1.7	21
157	Seasonal influenza vaccinations: specialized products for different target groups. <i>Vaccine</i> , 2010, 28, D14-D23.	1.7	5

#	ARTICLE	IF	CITATIONS
158	Establishing the baseline burden of influenza in preparation for the evaluation of a countywide school-based influenza vaccination campaign. <i>Vaccine</i> , 2010, 29, 123-129.	1.7	5
159	Considerations in the design of vaccines that induce CD8 T cell mediated immunity. <i>Vaccine</i> , 2010, 28, 7716-7722.	1.7	10
160	Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. <i>Vaccine</i> , 2010, 28, 8258-8267.	1.7	48
162	Human influenza vaccines and assessment of immunogenicity. <i>Expert Review of Vaccines</i> , 2010, 9, 1423-1439.	2.0	22
163	Influenza Vaccines: From Surveillance Through Production to Protection. <i>Mayo Clinic Proceedings</i> , 2010, 85, 257-273.	1.4	66
164	Cross-protective immunity to influenza A viruses. <i>Expert Review of Vaccines</i> , 2010, 9, 1325-1341.	2.0	105
165	Mucosal immunization: A realistic alternative. <i>Hum Vaccin</i> , 2010, 6, 978-1006.	2.4	42
166	Bench-to-bedside review: Vaccine protection strategies during pandemic flu outbreaks. <i>Critical Care</i> , 2010, 14, 218.	2.5	19
167	Antivirals for Influenza. <i>Paediatric Drugs</i> , 2010, 12, 285-299.	1.3	12
168	MF59 <sup>®</sup> -adjuvanted seasonal influenza vaccine in young children. <i>Expert Review of Vaccines</i> , 2011, 10, 1519-1528.	2.0	5
169	Delivery of antigens used for vaccination: recent advances and challenges. <i>Therapeutic Delivery</i> , 2011, 2, 1351-1368.	1.2	10
170	Epidemic Viral Pneumonia and Other Emerging Pathogens. <i>Clinics in Chest Medicine</i> , 2011, 32, 451-467.	0.8	7
171	Live Attenuated Influenza Vaccine (FluMist <sup>®</sup> ; Fluenz <sup>®</sup> ). <i>Drugs</i> , 2011, 71, 1591-1622.	4.9	189
172	The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2011, 53, e25-e76.	2.9	1,230
173	Potential of Nasopharynx-associated Lymphoid Tissue for Vaccine Responses in the Airways. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 183, 1595-1604.	2.5	142
174	Present and future of influenza prevention in pediatrics. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 641-653.	1.4	15
175	Protective immunity against malaria by "natural immunization" <sup>™</sup> : a question of dose, parasite diversity, or both?. <i>Current Opinion in Immunology</i> , 2011, 23, 500-508.	2.4	16
176	Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin. <i>Human Immunology</i> , 2011, 72, 463-469.	1.2	45

#	ARTICLE	IF	CITATIONS
177	The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons. <i>Vaccine</i> , 2011, 29, 1844-1849.	1.7	37
178	Bioprocess optimization for cell culture based influenza vaccine production. <i>Vaccine</i> , 2011, 29, 3320-3328.	1.7	36
179	Fever following administration of two inactivated influenza vaccines—A survey of parents of New Zealand infants and children 5 years of age and under. <i>Vaccine</i> , 2011, 29, 2933-2937.	1.7	10
180	Atopy history and the genomics of wheezing after influenza vaccination in children 6–59 months of age. <i>Vaccine</i> , 2011, 29, 3431-3437.	1.7	11
181	Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer. <i>Vaccine</i> , 2011, 29, 4110-4115.	1.7	32
182	A method for estimating vaccine-preventable pediatric influenza pneumonia hospitalizations in developing countries: Thailand as a case study. <i>Vaccine</i> , 2011, 29, 4416-4421.	1.7	4
183	Trends in US pediatric influenza vaccination from 2006 to 2010 among children with private insurance. <i>Vaccine</i> , 2011, 29, 4225-4229.	1.7	14
184	A survey of children's preferences for influenza vaccine attributes. <i>Vaccine</i> , 2011, 29, 4334-4340.	1.7	41
185	Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6–59 months of age. <i>Vaccine</i> , 2011, 29, 4322-4327.	1.7	38
186	Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. <i>Vaccine</i> , 2011, 29, 6379-6391.	1.7	57
187	A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years. <i>Vaccine</i> , 2011, 29, 4947-4952.	1.7	34
188	Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity. <i>Vaccine</i> , 2011, 29, 5304-5312.	1.7	37
189	Immunogenicity and safety of inactivated influenza vaccines in primed populations: A systematic literature review and meta-analysis. <i>Vaccine</i> , 2011, 29, 5785-5792.	1.7	73
190	A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. <i>Vaccine</i> , 2011, 29, 9159-9170.	1.7	133
191	Effectiveness and safety of influenza vaccination in children: European perspective. <i>Vaccine</i> , 2011, 29, 7529-7534.	1.7	32
192	Different influenza vaccine formulations and adjuvants for childhood influenza vaccination. <i>Vaccine</i> , 2011, 29, 7535-7541.	1.7	13
193	Immunogenicity and safety of intradermal influenza vaccine in children. <i>Vaccine</i> , 2011, 29, 7606-7610.	1.7	20
194	Vaccination contre la grippe : les recommandations sont-elles susceptibles d'évoluer en France ? <i>Archives De Pediatrie</i> , 2011, 18, H166-H167.	0.4	0

#	ARTICLE	IF	CITATIONS
195	The next decade of vaccines: societal and scientific challenges. <i>Lancet, The</i> , 2011, 378, 348-359.	6.3	63
196	Prevention of Fetal and Early Life Infections Through Maternalâ€œNeonatal Immunization. , 2011, , 1212-1230.		6
197	Influenza Vaccination in the Face of Immune Exhaustion: Is Herd Immunity Effective for Protecting the Elderly?. <i>Influenza Research and Treatment</i> , 2011, 2011, 1-6.	1.5	6
198	Cost-Effectiveness of 2009 Pandemic Influenza A(H1N1) Vaccination in the United States. <i>PLoS ONE</i> , 2011, 6, e22308.	1.1	37
199	Influenza Vaccination, Diagnosis, and Treatment in Children. <i>Pediatric Emergency Care</i> , 2011, 27, 760-769.	0.5	2
200	The Efficacy of Live Attenuated Influenza Vaccine Against Influenza-associated Acute Otitis Media in Children. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 203-207.	1.1	62
201	Pilot study of influenza vaccine effectiveness in urban Australian children attending childcare. <i>Journal of Paediatrics and Child Health</i> , 2011, 47, 857-862.	0.4	9
202	Immunogenomics and systems biology of vaccines. <i>Immunological Reviews</i> , 2011, 239, 197-208.	2.8	65
203	The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. <i>Influenza and Other Respiratory Viruses</i> , 2011, 5, 67-75.	1.5	154
204	An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17â€œyears. <i>Influenza and Other Respiratory Viruses</i> , 2011, 5, 389-397.	1.5	41
205	Intramuscular immunization of mice with live influenza virus is more immunogenic and offers greater protection than immunization with inactivated virus. <i>Virology Journal</i> , 2011, 8, 251.	1.4	20
206	Temperature-sensitive bacterial pathogens generated by the substitution of essential genes from cold-loving bacteria: potential use as live vaccines. <i>Journal of Molecular Medicine</i> , 2011, 89, 437-444.	1.7	6
207	Human body temperature and new approaches to constructing temperature-sensitive bacterial vaccines. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 3019-3031.	2.4	24
208	Antibiotic treatment of acute otitis media in pediatrics. <i>Future Microbiology</i> , 2011, 6, 485-488.	1.0	7
209	Influenza: Epidemiology, Clinical Features, Therapy, and Prevention. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 373-392.	0.8	83
211	Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. <i>Hum Vaccin</i> , 2011, 7, 29-40.	2.4	63
212	Effects of Adverse Events on the Projected Population Benefits and Cost-effectiveness of Using Live Attenuated Influenza Vaccine in Children Aged 6 Months to 4 Years. <i>JAMA Pediatrics</i> , 2011, 165, 112-8.	3.6	25
213	Infection of Lung Epithelial Cells with Pandemic 2009 A(H1N1) Influenza Viruses Reveals Isolate-Specific Differences in Infectivity and Host Cellular Responses. <i>Viral Immunology</i> , 2011, 24, 89-99.	0.6	7

#	ARTICLE	IF	CITATIONS
214	Randomized Controlled Trial of Dose Response to Influenza Vaccine in Children Aged 6 to 23 Months. <i>Pediatrics</i> , 2011, 128, e276-e289.	1.0	56
215	Clonally Related CD8+T Cells Responsible for Rapid Population of Both Diffuse Nasal-Associated Lymphoid Tissue and Lung After Respiratory Virus Infection. <i>Journal of Immunology</i> , 2011, 187, 835-841.	0.4	7
216	Pandemic Influenza. <i>Journal of Intensive Care Medicine</i> , 2011, 26, 347-367.	1.3	11
217	Influenza Vaccines for the Future. , 2011, , .		8
218	Live Attenuated Vaccines: Influenza, Rotavirus and Varicella Zoster Virus. , 2011, , 15-46.		3
219	Annual Vaccination against Influenza Virus Hampers Development of Virus-Specific CD8 <sup>+</sup> T Cell Immunity in Children. <i>Journal of Virology</i> , 2011, 85, 11995-12000.	1.5	84
220	Live and Inactivated Influenza Vaccines Induce Similar Humoral Responses, but Only Live Vaccines Induce Diverse T-Cell Responses in Young Children. <i>Journal of Infectious Diseases</i> , 2011, 204, 845-853.	1.9	267
221	Make New Friends, But Keep the Old: Influenza Vaccines in Children With Cancer. <i>Journal of Infectious Diseases</i> , 2011, 204, 1471-1474.	1.9	0
222	Adverse drug events monitoring of live attenuated pandemic influenza vaccine. <i>Indian Journal of Community Medicine</i> , 2011, 36, 234.	0.2	0
223	Oil-in-Water Emulsion Adjuvant with Influenza Vaccine in Young Children. <i>New England Journal of Medicine</i> , 2011, 365, 1406-1416.	13.9	291
224	Influenza Hemagglutination-Inhibition Antibody Titer as a Correlate of Vaccine-Induced Protection. <i>Journal of Infectious Diseases</i> , 2011, 204, 1879-1885.	1.9	246
225	Targeting influenza vaccinations of children. <i>Cmaj</i> , 2011, 183, 1464-1465.	0.9	1
226	Safety and Immunogenicity of Live Attenuated and Inactivated Influenza Vaccines in Children With Cancer. <i>Journal of Infectious Diseases</i> , 2011, 204, 1475-1482.	1.9	39
227	Effectiveness of Seasonal Influenza Vaccines in the United States During a Season With Circulation of All Three Vaccine Strains. <i>Clinical Infectious Diseases</i> , 2012, 55, 951-959.	2.9	227
228	The human side of influenza. <i>Journal of Leukocyte Biology</i> , 2012, 92, 83-96.	1.5	19
229	TLR7 Recognition Is Dispensable for Influenza Virus A Infection but Important for the Induction of Hemagglutinin-Specific Antibodies in Response to the 2009 Pandemic Split Vaccine in Mice. <i>Journal of Virology</i> , 2012, 86, 10988-10998.	1.5	58
230	Correlates of vaccine protection from influenza and its complications. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 34-44.	1.4	48
231	Immunogenicity and Safety of 2 Dose Levels of a Thimerosal-Free Trivalent Seasonal Influenza Vaccine in Children Aged 6-35 Months: A Randomized, Controlled Trial. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2012, 1, 55-63.	0.6	29

#	ARTICLE	IF	CITATIONS
232	Prevention of acute otitis media using currently available vaccines. <i>Future Microbiology</i> , 2012, 7, 457-465.	1.0	25
233	Expanding the Recommendations for Annual Influenza Vaccination to School-Age Children in the United States. <i>Pediatrics</i> , 2012, 129, S54-S62.	1.0	27
234	Influenza Vaccine in Young Children. <i>New England Journal of Medicine</i> , 2012, 366, 383-384.	13.9	4
235	Live attenuated intranasal influenza vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 76-80.	1.4	31
236	Quadrivalent Ann Arbor strain live-attenuated influenza vaccine. <i>Expert Review of Vaccines</i> , 2012, 11, 1293-1303.	2.0	32
237	Efficacy and safety of influenza vaccination in children with asthma. <i>Expert Review of Vaccines</i> , 2012, 11, 461-468.	2.0	9
238	Assessing the safety of influenza vaccination in specific populations: children and the elderly. <i>Expert Review of Vaccines</i> , 2012, 11, 973-984.	2.0	11
239	Attenuated Influenza Virus Construct with Enhanced Hemagglutinin Protein Expression. <i>Journal of Virology</i> , 2012, 86, 5782-5790.	1.5	16
240	The Receptor Binding Specificity of the Live Attenuated Influenza H2 and H6 Vaccine Viruses Contributes to Vaccine Immunogenicity and Protection in Ferrets. <i>Journal of Virology</i> , 2012, 86, 2780-2786.	1.5	19
241	Response to Christopher S. Ambrose: Use of live attenuated influenza vaccine in individuals with asthma or a history of wheezing. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 280-280.	1.4	0
242	Immunogenicity and Safety of a Quadrivalent Live Attenuated Influenza Vaccine in Children. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 745-751.	1.1	65
243	Preventing influenza in younger children. <i>Clinical Microbiology and Infection</i> , 2012, 18, 42-49.	2.8	20
246	A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18-49 years of age. <i>Vaccine</i> , 2012, 30, 3053-3060.	1.7	28
247	Biologically plausible and evidence-based risk intervals in immunization safety research. <i>Vaccine</i> , 2012, 31, 271-277.	1.7	46
248	A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season. <i>Vaccine</i> , 2012, 30, 6099-6102.	1.7	17
249	Report of the 5th meeting on influenza vaccines that induce broad spectrum and long-lasting immune responses, World Health Organization, Geneva, 16-17 November 2011. <i>Vaccine</i> , 2012, 30, 6612-6622.	1.7	8
250	The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. <i>Vaccine</i> , 2012, 30, 6794-6801.	1.7	97
251	Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. <i>Vaccine</i> , 2012, 31, 190-195.	1.7	69

#	ARTICLE	IF	CITATIONS
252	The Use of Live Attenuated Influenza Vaccine (LAIV) in Healthcare Personnel (HCP): Guidance from the Society for Healthcare Epidemiology of America (SHEA). <i>Infection Control and Hospital Epidemiology</i> , 2012, 33, 981-983.	1.0	7
253	Evolutionarily Conserved Essential Genes from Arctic Bacteria: A Tool for Vaccination. <i>Journal of Young Pharmacists</i> , 2012, 4, 55-57.	0.1	0
254	PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries. <i>Expert Review of Vaccines</i> , 2012, 11, 939-947.	2.0	7
255	Live Attenuated Influenza Vaccine (Fluenzâ„¢). <i>Paediatric Drugs</i> , 2012, 14, 271-279.	1.3	5
256	The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezing. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 2549-2557.	1.3	32
257	Vaccine-specific antibody secreting cells are a robust early marker of LAIV-induced B-cell response in ferrets. <i>Vaccine</i> , 2012, 30, 237-246.	1.7	12
258	The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized controlled studies. <i>Vaccine</i> , 2012, 30, 886-892.	1.7	90
259	A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age. <i>Vaccine</i> , 2012, 30, 2989-2998.	1.7	30
260	Engineering temperature sensitive live attenuated influenza vaccines from emerging viruses. <i>Vaccine</i> , 2012, 30, 3691-3702.	1.7	34
261	Comparative Study of Influenza Virus Replication in MDCK Cells and in Primary Cells Derived from Adenoids and Airway Epithelium. <i>Journal of Virology</i> , 2012, 86, 11725-11734.	1.5	56
262	Evaluation of Influenza Virus A/H3N2 and B Vaccines on the Basis of Cross-Reactivity of Postvaccination Human Serum Antibodies against Influenza Viruses A/H3N2 and B Isolated in MDCK Cells and Embryonated Hen Eggs. <i>Vaccine Journal</i> , 2012, 19, 897-908.	3.2	30
263	Otitis media. <i>Future Microbiology</i> , 2012, 7, 733-753.	1.0	29
264	Can mucosal adjuvants contribute to the induction of immunological memory induced via unconjugated T-cell-independent antigens?. <i>Journal of Drug Targeting</i> , 2012, 20, 502-508.	2.1	2
266	Development of Live-Attenuated Influenza Vaccines against Outbreaks of H5N1 Influenza. <i>Viruses</i> , 2012, 4, 3589-3605.	1.5	8
267	Viralâ€“Bacterial Interactions in Acute Otitis Media. <i>Current Allergy and Asthma Reports</i> , 2012, 12, 551-558.	2.4	73
269	Economic Evaluations of Childhood Influenza Vaccination. <i>Pharmacoeconomics</i> , 2012, 30, 647-660.	1.7	20
270	Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 287.	0.7	19
271	Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. <i>Reviews in Medical Virology</i> , 2012, 22, 267-279.	3.9	82

#	ARTICLE	IF	CITATIONS
272	Mucosal immunity and nasal influenza vaccination. Expert Review of Vaccines, 2012, 11, 595-607.	2.0	82
273	The potential economic value of a "universal" (multi-year) influenza vaccine. Influenza and Other Respiratory Viruses, 2012, 6, 167-175.	1.5	14
274	Mucosal antibody responses are directed by viral burden in children with acute influenza infection. Influenza and Other Respiratory Viruses, 2013, 7, 46-54.	1.5	3
275	An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza and Other Respiratory Viruses, 2013, 7, 66-73.	1.5	38
276	Vaccines for preventing influenza in people with asthma. The Cochrane Library, 2013, , CD000364.	1.5	82
277	Correlates of protection against influenza infection in humans"on the path to a universal vaccine?. Current Opinion in Immunology, 2013, 25, 470-476.	2.4	40
278	Influenza vaccine"live. , 2013, , 294-311.		2
279	Safety and immune responses following administration of H1N1 live attenuated influenza vaccine in Thais. Vaccine, 2013, 31, 1503-1509.	1.7	12
280	Evaluation of the Humoral and Cellular Immune Responses Elicited by the Live Attenuated and Inactivated Influenza Vaccines and Their Roles in Heterologous Protection in Ferrets. Journal of Infectious Diseases, 2013, 208, 594-602.	1.9	78
281	Challenges and Opportunities for Respiratory Syncytial Virus Vaccines. Current Topics in Microbiology and Immunology, 2013, , .	0.7	8
282	Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1. Vaccine, 2013, 31, 6194-6200.	1.7	43
283	Background paper to the recommendation for the preferential use of live-attenuated influenza vaccine in children aged 2-6 years in Germany. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2013, 56, 1557-1564.	7.2	12
286	Influenza Virus Subpopulations: Interferon Induction-Suppressing Particles Require Expression of NS1 and Act Globally in Cells; UV Irradiation of Interferon-Inducing Particles Blocks Global Shut-Off and Enhances Interferon Production. Journal of Interferon and Cytokine Research, 2013, 33, 72-79.	0.5	3
287	Alternative vaccine delivery methods. , 2013, , 1200-1231.		48
288	Cost-effectiveness of childhood influenza vaccination in England and Wales: Results from a dynamic transmission model. Vaccine, 2013, 31, 927-942.	1.7	64
289	Afriflu2"Second international workshop on influenza vaccination in the African continent"8 November 2012, Cape Town (South Africa). Vaccine, 2013, 31, 3461-3466.	1.7	9
290	A postlicensure evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 24-59 months of age. Vaccine, 2013, 31, 1812-1818.	1.7	21
291	Current developments and trends in childhood immunization. Paediatrics and Child Health (United Tj ETQq1 1 0.784314 rgBJ /Overlo	0,2	2



#	ARTICLE	IF	CITATIONS
292	Vaccines as a tool to estimate the burden of severe influenza in children of low-resourced areas (November 30–December 1, 2012, Les Pensieres, Veyrier-du-Lac, France). <i>Vaccine</i> , 2013, 31, 3222-3228.	1.7	25
293	Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review. <i>Drug Delivery and Translational Research</i> , 2013, 3, 42-62.	3.0	379
294	Influenza Viruses with Rearranged Genomes as Live-Attenuated Vaccines. <i>Journal of Virology</i> , 2013, 87, 5118-5127.	1.5	57
295	The status of live viral vaccination in early life. <i>Vaccine</i> , 2013, 31, 2531-2537.	1.7	11
296	Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1. <i>Scientific Reports</i> , 2013, 3, 1443.	1.6	67
297	Pneumonia in low and middle income countries: progress and challenges. <i>Thorax</i> , 2013, 68, 1052-1056.	2.7	99
299	Comparison of the Effectiveness of Trivalent Inactivated Influenza Vaccine and Live, Attenuated Influenza Vaccine in Preventing Influenza-Like Illness Among US Military Service Members, 2006-2009. <i>Clinical Infectious Diseases</i> , 2013, 56, 11-19.	2.9	15
300	Vaccinophobia and Vaccine Controversies of the 21st Century. , 2013, , .		5
301	Should all children be immunised against influenza?. <i>Archives of Disease in Childhood</i> , 2013, 98, 846-849.	1.0	11
302	School-Located Influenza Vaccination and Absenteeism Among Elementary School Students in a Hispanic Community. <i>Journal of School Nursing</i> , 2013, 29, 271-283.	0.9	5
303	Overview of Influenza Vaccines in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2013, 2, 368-378.	0.6	13
304	Recombinant IgA Is Sufficient To Prevent Influenza Virus Transmission in Guinea Pigs. <i>Journal of Virology</i> , 2013, 87, 7793-7804.	1.5	73
305	Vaccinations for healthcare personnel. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 366-377.	1.3	8
306	Differential localization and function of antibody-forming cells responsive to inactivated or live-attenuated influenza virus vaccines. <i>International Immunology</i> , 2013, 25, 183-195.	1.8	24
307	Cross-protection against drifted influenza viruses. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 582-590.	1.4	30
308	Live-Attenuated Respiratory Syncytial Virus Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2013, 372, 259-284.	0.7	116
309	Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraproductive live vaccine in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9481-9486.	3.3	91
310	Intranasal influenza vaccination using a new synthetic mucosal adjuvant SF10: induction of potent local and systemic immunity with balanced Th1 and Th2 responses. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 1218-1226.	1.5	17

#	ARTICLE	IF	CITATIONS
311	The Diagnosis and Management of Acute Otitis Media. <i>Pediatrics</i> , 2013, 131, e964-e999.	1.0	988
312	Assessing vaccine efficacy in influenza clinical trials: challenges and difficulties. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 403-411.	1.3	4
313	Adjuvanted versus nonadjuvanted influenza vaccines in young children: comparing results from recent clinical trials. <i>Clinical Investigation</i> , 2013, 3, 395-408.	0.0	1
314	Universal flu vaccination for children starts. <i>Practice Nursing</i> , 2013, 24, 432-436.	0.1	1
315	Changes to this year's immunisation schedule. <i>Primary Health Care</i> , 2013, 23, 24-27.	0.0	3
316	Timeliness of Pediatric Influenza Vaccination Compared With Seasonal Influenza Activity in an Urban Community, 2004-2008. <i>American Journal of Public Health</i> , 2013, 103, e50-e58.	1.5	11
317	Effectiveness of Intranasal Live Attenuated Influenza Vaccine Against All-cause Acute Otitis Media in Children. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 669-674.	1.1	36
318	Vaccination of Healthy Children Against Seasonal Influenza. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 881-888.	1.1	34
319	Cross-Protective Immune Responses Elicited by Live Attenuated Influenza Vaccines. <i>Yonsei Medical Journal</i> , 2013, 54, 271.	0.9	30
320	Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age. <i>PLoS ONE</i> , 2013, 8, e77104.	1.1	66
321	Universal flu vaccination for children gets underway. <i>Independent Nurse</i> , 2013, 2013, 20-22.	0.0	1
322	Introduction of a new childhood influenza vaccination programme. <i>Journal of Health Visiting</i> , 2013, 1, 640-646.	0.0	0
323	Extending universal flu vaccination for children. <i>Practice Nursing</i> , 2014, 25, 446-450.	0.1	0
324	Positive Network Assortativity of Influenza Vaccination at a High School: Implications for Outbreak Risk and Herd Immunity. <i>PLoS ONE</i> , 2014, 9, e87042.	1.1	76
326	T-Cell Immunity to Influenza A Viruses. <i>Critical Reviews in Immunology</i> , 2014, 34, 15-39.	1.0	23
327	Intranasal LAIV preferred for children 2 to 8 years of age. <i>Pharmacy Today</i> , 2014, 20, 44.	0.0	0
328	Development of one-step real-time PCR assay for titrating trivalent live attenuated influenza vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3642-3648.	1.4	9
329	Influenza Viruses. , 2014, , 455-478.		5

#	ARTICLE	IF	CITATIONS
330	School-Located Influenza Vaccination Decreases Laboratory-Confirmed Influenza and Improves School Attendance. <i>Clinical Infectious Diseases</i> , 2014, 59, 325-332.	2.9	65
332	Considerations for the rapid deployment of vaccines against H7N9 influenza. <i>Expert Review of Vaccines</i> , 2014, 13, 1327-1337.	2.0	4
333	Fast vaccine design and development based on correlates of protection (COPs): Influenza as a trendsetter. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1935-1948.	1.4	16
334	Efficacy of live attenuated influenza vaccine against influenza illness in children as a function of illness severity. <i>Vaccine</i> , 2014, 32, 5546-5548.	1.7	14
335	Live Attenuated Influenza Vaccine Enhances Colonization of <i>Streptococcus pneumoniae</i> and <i>Staphylococcus aureus</i> in Mice. <i>MBio</i> , 2014, 5, .	1.8	83
336	No Clinical Association of Live Attenuated Influenza Virus with Nasal Carriage of Bacteria or Acute Otitis Media. <i>MBio</i> , 2014, 5, e01145-14.	1.8	2
337	Making evidence-based selections of influenza vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 2729-2732.	1.4	5
338	Recommendations for Prevention and Control of Influenza in Children, 2014-2015. <i>Pediatrics</i> , 2014, 134, e1503-e1519.	1.0	27
339	The alphabet soup describing licensed influenza vaccines. <i>Reviews in Medical Virology</i> , 2014, 24, 1-2.	3.9	0
340	Effectiveness of influenza vaccine in children in day-care centers of <sc>S</sc>apporo. <i>Pediatrics International</i> , 2014, 56, 53-56.	0.2	2
341	Newcastle Disease Virus Vector Producing Human Norovirus-Like Particles Induces Serum, Cellular, and Mucosal Immune Responses in Mice. <i>Journal of Virology</i> , 2014, 88, 9718-9727.	1.5	34
342	Deciding who should get live attenuated influenza vaccine. <i>Reviews in Medical Virology</i> , 2014, 24, 289-290.	3.9	0
343	Assessing the Evidence. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, e106-e115.	1.1	10
344	Prevention and Control of Seasonal Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2014-15 Influenza Season. <i>American Journal of Transplantation</i> , 2014, 14, 2906-2913.	2.6	137
345	Live attenuated influenza vaccine strains elicit a greater innate immune response than antigenically-matched seasonal influenza viruses during infection of human nasal epithelial cell cultures. <i>Vaccine</i> , 2014, 32, 1761-1767.	1.7	28
346	Differences in Antibody Responses Between Trivalent Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine Correlate With the Kinetics and Magnitude of Interferon Signaling in Children. <i>Journal of Infectious Diseases</i> , 2014, 210, 224-233.	1.9	69
348	Production of live attenuated influenza vaccines against seasonal and potential pandemic influenza viruses. <i>Current Opinion in Virology</i> , 2014, 6, 34-39.	2.6	26
349	Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. <i>Vaccine</i> , 2014, 32, 6798-6804.	1.7	65

#	ARTICLE	IF	CITATIONS
350	Vaccinating High-Risk Children with the Intranasal Live-Attenuated Influenza Vaccine: the Quebec Experience. <i>Paediatric Respiratory Reviews</i> , 2014, 15, 340-347.	1.2	6
351	An Alphavirus-Based Adjuvant Enhances Serum and Mucosal Antibodies, T Cells, and Protective Immunity to Influenza Virus in Neonatal Mice. <i>Journal of Virology</i> , 2014, 88, 9182-9196.	1.5	11
352	Safety of Live-Attenuated Influenza Vaccination in Cystic Fibrosis. <i>Pediatrics</i> , 2014, 134, e983-e991.	1.0	14
353	Live Attenuated Influenza Vaccine. <i>Current Topics in Microbiology and Immunology</i> , 2014, 386, 181-204.	0.7	58
354	Memory CD4 T Cells in Influenza. <i>Current Topics in Microbiology and Immunology</i> , 2014, 386, 399-421.	0.7	69
355	Parents' preferences for seasonal influenza vaccine for their children in Japan. <i>Vaccine</i> , 2014, 32, 5071-5076.	1.7	36
356	Distinct Cross-reactive B-Cell Responses to Live Attenuated and Inactivated Influenza Vaccines. <i>Journal of Infectious Diseases</i> , 2014, 210, 865-874.	1.9	26
357	Induction of protective immunity against H1N1 influenza A(H1N1)pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates. <i>Vaccine</i> , 2014, 32, 2231-2240.	1.7	23
358	Influenza and Parainfluenza Viral Infections in Children. <i>Pediatrics in Review</i> , 2014, 35, 217-228.	0.2	17
359	Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: A Phase I dose escalating study in healthy volunteers. <i>Vaccine</i> , 2014, 32, 5118-5124.	1.7	5
361	Clinical and Immune Responses to Inactivated Influenza A(H1N1)pdm09 Vaccine in Children. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 865-871.	1.1	10
362	Parental Views on Childhood Influenza Vaccination. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 334-335.	1.1	4
363	Detection of a NDM-1-producing <i>Klebsiella pneumoniae</i> (ST22) Clinical Isolate at a Pediatric Hospital in Mexico. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 335.	1.1	24
364	Post-Licensure Surveillance of Trivalent Live-Attenuated Influenza Vaccine in Children Aged 2-18 Years, Vaccine Adverse Event Reporting System, United States, July 2005-June 2012. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 205-213.	0.6	17
365	Influenza vaccines for preventing acute otitis media in infants and children. , 2015, , CD010089.		19
366	Parental perceptions and predictors of consent for school-located influenza vaccination in urban elementary school children in the United States. <i>Influenza and Other Respiratory Viruses</i> , 2015, 9, 255-262.	1.5	10
367	Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. <i>BMJ, The</i> , 2015, 351, h6291.	3.0	50
368	Immunizations in Pediatric and Adult Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1993-2003.	0.9	20

#	ARTICLE	IF	CITATIONS
369	Safety of influenza vaccination in children with allergic diseases. <i>Clinical and Experimental Vaccine Research</i> , 2015, 4, 137.	1.1	4
370	Emerging Influenza Strains in the Last Two Decades: A Threat of a New Pandemic?. <i>Vaccines</i> , 2015, 3, 172-185.	2.1	32
371	Boosted Influenza-Specific T Cell Responses after H5N1 Pandemic Live Attenuated Influenza Virus Vaccination. <i>Frontiers in Immunology</i> , 2015, 6, 287.	2.2	25
372	Effectiveness of the 2012/13 Trivalent Live and Inactivated Influenza Vaccines in Children and Adolescents in Saxony-Anhalt, Germany: A Test-Negative Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0122910.	1.1	20
373	Influenza (Including Avian Influenza and Swine Influenza). , 2015, , 2000-2024.e6.		15
375	Immunobiology of the Tonsils and Adenoids. , 2015, , 1985-2016.		25
376	Prevention and Control of Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015â€“16 Influenza Season. <i>American Journal of Transplantation</i> , 2015, 15, 2767-2775.	2.6	25
378	Intranasal immunisation with recombinant adenovirus vaccines protects against a lethal challenge with pneumonia virus of mice. <i>Vaccine</i> , 2015, 33, 6641-6649.	1.7	7
379	The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper. <i>Vaccine</i> , 2015, 33, F1-F67.	1.7	39
380	Safe vaccination of patients with egg allergy by using live attenuated influenza vaccine. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 138-139.	2.0	26
381	Live Attenuated Influenza Virus Increases Pneumococcal Translocation and Persistence Within the Middle Ear. <i>Journal of Infectious Diseases</i> , 2015, 212, 195-201.	1.9	21
382	Live Attenuated and Inactivated Influenza Vaccines in Children. <i>Journal of Infectious Diseases</i> , 2015, 211, 352-360.	1.9	40
383	Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines. <i>Vaccines</i> , 2015, 3, 373-389.	2.1	151
384	Longevity of B-Cell and T-Cell Responses After Live Attenuated Influenza Vaccination in Children. <i>Journal of Infectious Diseases</i> , 2015, 211, 1541-1549.	1.9	62
385	Current Influenza Vaccine Options for 2014. <i>Current Emergency and Hospital Medicine Reports</i> , 2015, 3, 126-133.	0.6	0
386	Protection of young children from influenza through universal vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2350-2358.	1.4	12
387	Downregulating viral gene expression: codon usage bias manipulation for the generation of novel influenza A virus vaccines. <i>Future Virology</i> , 2015, 10, 715-730.	0.9	33
388	Live attenuated influenza vaccine tetravalent: a clinical review. <i>Expert Review of Vaccines</i> , 2015, 14, 963-973.	2.0	9

#	ARTICLE	IF	CITATIONS
389	H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 970-982.	1.4	21
390	Mannan adjuvants intranasally administered inactivated influenza virus in mice rendering low doses inductive of strong serum IgG and IgA in the lung. <i>BMC Infectious Diseases</i> , 2015, 15, 101.	1.3	9
391	Enhanced immune responses by skin vaccination with influenza subunit vaccine in young hosts. <i>Vaccine</i> , 2015, 33, 4675-4682.	1.7	38
392	Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season. <i>Journal of Infectious Diseases</i> , 2015, 212, 726-739.	1.9	66
393	Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh. <i>Vaccine</i> , 2015, 33, 3415-3421.	1.7	21
394	Targeted vaccination in healthy school children - Can primary school vaccination alone control influenza?. <i>Vaccine</i> , 2015, 33, 5415-5424.	1.7	17
395	Wheeze as an adverse event in pediatric vaccine and drug randomized controlled trials: A systematic review. <i>Vaccine</i> , 2015, 33, 5333-5341.	1.7	6
396	Influenza vaccination type, live, attenuated influenza vaccine (LAIV) versus inactivated influenza vaccine (IIV), received by children, United States, 2011-2012 through 2013-2014 influenza seasons. <i>Vaccine</i> , 2015, 33, 5196-5203.	1.7	4
397	The UK immunisation schedule: changes to vaccine policy and practice in 2013/14. <i>JRSM Open</i> , 2015, 6, 205427041557776.	0.2	11
398	Safety, immunogenicity and infectivity of new live attenuated influenza vaccines. <i>Expert Review of Vaccines</i> , 2015, 14, 1313-1329.	2.0	30
399	Safety of live attenuated influenza vaccine in atopic children with egg allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 376-381.	1.5	56
400	Protective antibody responses against A(H1N1)pdm09 primed by infection and recalled by intranasal vaccination. <i>Vaccine</i> , 2015, 33, 6066-6069.	1.7	1
401	Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1488.	3.8	81
402	Influenza vaccination in children primed with MF59 <sup>®</sup> -adjuvanted or non-adjuvanted seasonal influenza vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2102-2112.	1.4	21
403	Generation of Live Attenuated Influenza Virus by Using Codon Usage Bias. <i>Journal of Virology</i> , 2015, 89, 10762-10773.	1.5	38
404	Restricted replication of the live attenuated influenza A virus vaccine during infection of primary differentiated human nasal epithelial cells. <i>Vaccine</i> , 2015, 33, 4495-4504.	1.7	29
405	FluMist. <i>Clinical Pediatrics</i> , 2015, 54, 1021-1021.	0.4	1
406	Immunizations in solid organ and hematopoietic stem cell transplant patients: A comprehensive review. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2852-2863.	1.4	17

#	ARTICLE	IF	CITATIONS
408	Efficacy and effectiveness of live attenuated influenza vaccine in school-age children. <i>Expert Review of Vaccines</i> , 2015, 14, 1331-1346.	2.0	29
410	Prevention of Influenza in Children. <i>Infectious Disease Clinics of North America</i> , 2015, 29, 597-615.	1.9	7
411	Distinct Patterns of B-Cell Activation and Priming by Natural Influenza Virus Infection Versus Inactivated Influenza Vaccination. <i>Journal of Infectious Diseases</i> , 2015, 211, 1051-1059.	1.9	27
412	Increasing uptake of live attenuated influenza vaccine among children in the United States, 2008â€“2014. <i>Vaccine</i> , 2015, 33, 22-24.	1.7	17
414	Biodrug Delivery Systems. , 0, , .		6
415	Influenza Virus. , 2016, , 1009-1058.		5
416	Influenza and Memory T Cells: How to Awake the Force. <i>Vaccines</i> , 2016, 4, 33.	2.1	30
417	Trivalent inactivated influenza vaccine effective against influenza A(H3N2) variant viruses in children during the 2014/15 season, Japan. <i>Eurosurveillance</i> , 2016, 21, .	3.9	24
418	Role of Vaccines. , 2016, , 219-233.		0
419	Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines. <i>Viruses</i> , 2016, 8, 183.	1.5	94
420	Immune Responses to Circulating and Vaccine Viral Strains in HIV-Infected and Uninfected Children and Youth Who Received the 2013/2014 Quadrivalent Live-Attenuated Influenza Vaccine. <i>Frontiers in Immunology</i> , 2016, 7, 142.	2.2	3
421	Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge. <i>PLoS ONE</i> , 2016, 11, e0161193.	1.1	103
422	Nanotechnologies Applied in Biomedicinesâ€™ Vaccine. , 0, , .		8
423	Influenza Vaccine is Protective Against Laboratory-confirmed Influenza in Obese Children. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 440-445.	1.1	14
424	Assessing Fever Frequency After Pediatric Live Attenuated Versus Inactivated Influenza Vaccination. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2017, 6, piw028.	0.6	7
425	Cost-effectiveness analysis of the direct and indirect impact of intranasal live attenuated influenza vaccination strategies in children: alternative country profiles. <i>Journal of Market Access &amp; Health Policy</i> , 2016, 4, 31205.	0.8	6
427	Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial. <i>The Lancet Global Health</i> , 2016, 4, e946-e954.	2.9	46
428	Live Attenuated Versus Inactivated Influenza Vaccine in Hutterite Children. <i>Annals of Internal Medicine</i> , 2016, 165, 617.	2.0	33

#	ARTICLE	IF	CITATIONS
429	Advances in novel influenza vaccines: a patent review. <i>Journal of Microbiology</i> , 2016, 54, 403-412.	1.3	5
430	Production of Influenza Virus HA1 Harboring Native-Like Epitopes by <i>Pichia pastoris</i> . <i>Applied Biochemistry and Biotechnology</i> , 2016, 179, 1275-1289.	1.4	4
431	Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines. <i>Journal of Virology</i> , 2016, 90, 6291-6302.	1.5	44
432	Improving influenza vaccination in chronically ill children using a tertiary-care based vaccination clinic: Is there a role for the live-attenuated influenza vaccine (LAIV)? <i>Vaccine</i> , 2016, 34, 750-756.	1.7	6
433	Challenges Remain for Influenza Vaccination of Children. <i>Journal of Infectious Diseases</i> , 2016, 214, 1470-1472.	1.9	0
434	Reasons for influenza vaccination underutilization: A case-control study. <i>American Journal of Infection Control</i> , 2016, 44, 1084-1088.	1.1	4
436	Influenza Vaccines and Vaccination Strategies. , 2016, , 423-444.		4
437	Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics – a systematic literature review. <i>Influenza and Other Respiratory Viruses</i> , 2016, 10, 254-267.	1.5	66
438	Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus. <i>Journal of Virology</i> , 2016, 90, 8454-8463.	1.5	42
439	Neutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination. <i>Vaccine Journal</i> , 2016, 23, 831-839.	3.2	19
440	Otitis media. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16063.	18.1	332
441	Influenza. <i>BMJ, The</i> , 2016, 355, i6258.	3.0	109
442	Factors associated with influenza vaccine uptake during a universal vaccination programme of preschool children in England and Wales: a cohort study. <i>Journal of Epidemiology and Community Health</i> , 2016, 70, 1082-1087.	2.0	18
443	Correlates of Immunity to Influenza as Determined by Challenge of Children with Live, Attenuated Influenza Vaccine. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw108.	0.4	36
444	A critical role of T follicular helper cells in human mucosal anti-influenza response that can be enhanced by immunological adjuvant CpG-DNA. <i>Antiviral Research</i> , 2016, 132, 122-130.	1.9	9
445	Clinical and socioeconomic impact of moderate-to-severe versus mild influenza in children. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2016, 35, 1107-1113.	1.3	16
446	Effect of risk factors on the prevalence of influenza infections among children of slums of Dhaka city. <i>SpringerPlus</i> , 2016, 5, 602.	1.2	10
447	The Effects of Live Attenuated Influenza Vaccine on Nasopharyngeal Bacteria in Healthy 2 to 4 Year Olds. A Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 1401-1409.	2.5	38



#	ARTICLE	IF	CITATIONS
448	Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine. <i>Pediatrics</i> , 2016, 137, e20153279.	1.0	80
449	Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9). <i>Journal of Infectious Diseases</i> , 2016, 213, 922-929.	1.9	45
450	Possible Impact of Yearly Childhood Vaccination With Trivalent Inactivated Influenza Vaccine (TIV) on the Immune Response to the Pandemic Strain H1N1. <i>Clinical Pediatrics</i> , 2016, 55, 245-250.	0.4	1
451	Substantial Influenza Vaccine Effectiveness in Households With Children During the 2013â€“2014 Influenza Season, When 2009 Pandemic Influenza A(H1N1) Virus Predominated. <i>Journal of Infectious Diseases</i> , 2016, 213, 1229-1236.	1.9	50
452	Induction of systemic and mucosal immunity and maintenance of its memory against influenza A virus by nasal vaccination using a new mucosal adjuvant SF-10 derived from pulmonary surfactant in young cynomolgus monkeys. <i>Vaccine</i> , 2016, 34, 1881-1888.	1.7	12
453	Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013â€“2014 in the United States. <i>Journal of Infectious Diseases</i> , 2016, 213, 1546-1556.	1.9	159
454	A Single Mutation at PB1 Residue 319 Dramatically Increases the Safety of PR8 Live Attenuated Influenza Vaccine in a Murine Model without Compromising Vaccine Efficacy. <i>Journal of Virology</i> , 2016, 90, 2702-2705.	1.5	13
455	Systems vaccinology informs influenza vaccine immunogenicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1689-1691.	3.3	8
456	Influenza immunology evaluation and correlates of protection: a focus on vaccines. <i>Expert Review of Vaccines</i> , 2016, 15, 967-976.	2.0	90
458	Hospitalizations within 14 days of vaccination among pediatric recipients of the live attenuated influenza vaccine, United States 2010â€“2012. <i>Vaccine</i> , 2017, 35, 529-535.	1.7	4
459	A Feasibility Trial of Home Administration of Intranasal Vaccine by Parents to Eligible Children. <i>Clinical Therapeutics</i> , 2017, 39, 204-211.e4.	1.1	6
460	The Advisory Committee on Immunization Practicesâ€™ controversial recommendation against the use of live attenuated influenza vaccine is based on a biased study design that ignores secondary protection. <i>Vaccine</i> , 2017, 35, 1110-1112.	1.7	9
461	A live-attenuated influenza vaccine for H3N2 canine influenza virus. <i>Virology</i> , 2017, 504, 96-106.	1.1	27
463	Prevention and control of influenza in children during the 2016â€“2017 seasonal epidemic. <i>Journal for Specialists in Pediatric Nursing</i> , 2017, 22, e12173.	0.6	1
464	Generation of a Live Attenuated Influenza Vaccine that Elicits Broad Protection in Mice and Ferrets. <i>Cell Host and Microbe</i> , 2017, 21, 334-343.	5.1	24
465	Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2â€“49years. <i>Vaccine</i> , 2017, 35, 1254-1258.	1.7	24
466	Factors affecting induction of peripheral IFN- $\beta$ recall response to influenza A virus vaccination in pigs. <i>Veterinary Immunology and Immunopathology</i> , 2017, 185, 57-65.	0.5	15
467	Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines. <i>Vaccine</i> , 2017, 35, 2668-2675.	1.7	15

#	ARTICLE	IF	CITATIONS
468	Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014â€“2015 season. <i>Vaccine</i> , 2017, 35, 2685-2693.	1.7	30
469	A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	189
470	Vaccines in the Prevention of Viral Pneumonia. <i>Clinics in Chest Medicine</i> , 2017, 38, 155-169.	0.8	8
471	NS1 Protein Amino Acid Changes D189N and V194I Affect Interferon Responses, Thermosensitivity, and Virulence of Circulating H3N2 Human Influenza A Viruses. <i>Journal of Virology</i> , 2017, 91, .	1.5	43
472	Temperature-Sensitive Live-Attenuated Canine Influenza Virus H3N8 Vaccine. <i>Journal of Virology</i> , 2017, 91, .	1.5	23
473	The M2 protein of live, attenuated influenza vaccine encodes a mutation that reduces replication in human nasal epithelial cells. <i>Vaccine</i> , 2017, 35, 6691-6699.	1.7	20
474	A multi-site feasibility study to assess fever and wheezing in children after influenza vaccines using text messaging. <i>Vaccine</i> , 2017, 35, 6941-6948.	1.7	5
475	Changes in Influenza Vaccination Rates After Withdrawal of Live Vaccine. <i>Pediatrics</i> , 2017, 140, .	1.0	5
476	Influenza vaccines for preventing acute otitis media in infants and children. <i>The Cochrane Library</i> , 2017, 2017, CD010089.	1.5	33
477	The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014â€“2015 Influenza Vaccine. <i>Clinical Infectious Diseases</i> , 2017, 65, 1644-1651.	2.9	36
478	Epidemiological Methods. <i>Methods in Molecular Biology</i> , 2017, 1656, 263-271.	0.4	0
479	Reduced generation of lung tissueâ€“resident memory T cells during infancy. <i>Journal of Experimental Medicine</i> , 2017, 214, 2915-2932.	4.2	76
480	Tissue compartmentalization of T cell responses during early life. <i>Seminars in Immunopathology</i> , 2017, 39, 593-604.	2.8	12
481	Influenza A haemagglutinin specific IgG responses in children and adults after seasonal trivalent live attenuated influenza vaccination. <i>Vaccine</i> , 2017, 35, 5666-5673.	1.7	15
482	Influenza A Virus Studies in a Mouse Model of Infection. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	26
483	Influenza. <i>Pediatric Clinics of North America</i> , 2017, 64, 911-936.	0.9	13
484	Influenza vaccines effectiveness 2013â€“14 through 2015â€“16, a test-negative study in children. <i>Vaccine</i> , 2017, 35, 4088-4093.	1.7	9
485	Influenza vaccination rates in children decline when the live attenuated influenza vaccine is not recommended. <i>Vaccine</i> , 2017, 35, 5278-5282.	1.7	8

#	ARTICLE	IF	CITATIONS
486	Adverse events following live-attenuated intranasal influenza vaccination of children with cystic fibrosis: Results from two influenza seasons. <i>Vaccine</i> , 2017, 35, 5019-5026.	1.7	1
487	Evidence for Health Decision Making â€” Beyond Randomized, Controlled Trials. <i>New England Journal of Medicine</i> , 2017, 377, 465-475.	13.9	563
488	Influenza Vaccine Effectiveness in the United States during the 2015â€“2016 Season. <i>New England Journal of Medicine</i> , 2017, 377, 534-543.	13.9	240
490	Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus. <i>Vaccine</i> , 2017, 35, 5297-5302.	1.7	34
492	A bivalent live-attenuated influenza vaccine for the control and prevention of H3N8 and H3N2 canine influenza viruses. <i>Vaccine</i> , 2017, 35, 4374-4381.	1.7	14
493	Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a Promising Influenza Vaccine Candidate. <i>Viral Immunology</i> , 2017, 30, 451-462.	0.6	33
494	The History of Therapeutic Aerosols: A Chronological Review. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2017, 30, 20-41.	0.7	194
495	Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults. <i>Vaccine Journal</i> , 2017, 24, .	3.2	106
496	Canine influenza viruses with modified NS1 proteins for the development of live-attenuated vaccines. <i>Virology</i> , 2017, 500, 1-10.	1.1	28
497	First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virusâ€“Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. <i>Journal of Infectious Diseases</i> , 2017, 215, 95-104.	1.9	38
498	Live attenuated influenza vaccine for children. <i>Drug and Therapeutics Bulletin</i> , 2017, 55, 114-117.	0.3	5
499	An Adenovirus-Vectored Influenza Vaccine Induces Durable Cross-Protective Hemagglutinin Stalk Antibody Responses in Mice. <i>Viruses</i> , 2017, 9, 234.	1.5	18
500	Reverse Genetics Approaches for the Development of Influenza Vaccines. <i>International Journal of Molecular Sciences</i> , 2017, 18, 20.	1.8	90
501	Mucosal and Systemic Immune Responses to Influenza H7N9 Antigen HA1â€“2 Co-Delivered Intranasally with Flagellin or Polyethyleneimine in Mice and Chickens. <i>Frontiers in Immunology</i> , 2017, 8, 326.	2.2	35
502	AS03- and MF59-Adjuvanted Influenza Vaccines in Children. <i>Frontiers in Immunology</i> , 2017, 8, 1760.	2.2	109
503	Comparative analysis of virus-host interactions caused by a virulent and an attenuated duck hepatitis A virus genotype 1. <i>PLoS ONE</i> , 2017, 12, e0178993.	1.1	35
504	Live-Attenuated Influenza Vaccine Effectiveness in Children From 2009 to 2015â€“2016: A Systematic Review and Meta-Analysis. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx111.	0.4	59
505	H5N2 vaccine viruses on Russian and US live attenuated influenza virus backbones demonstrate similar infectivity, immunogenicity and protection in ferrets. <i>Vaccine</i> , 2018, 36, 1871-1879.	1.7	4

#	ARTICLE	IF	CITATIONS
506	Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013â€“2014 season. <i>Vaccine</i> , 2018, 36, 1214-1219.	1.7	18
507	Crafting Live-Attenuated Vaccines Against Respiratory Syncytial Virus. <i>Journal of Infectious Diseases</i> , 2018, 217, 1335-1337.	1.9	2
508	2015â€“2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 665-672.	2.9	52
509	Change in the efficacy of influenza vaccination after repeated inoculation under antigenic mismatch: A systematic review and meta-analysis. <i>Vaccine</i> , 2018, 36, 949-957.	1.7	19
510	<i>Influenza Viruses.</i> , 2018, , 1181-1190.e5.		2
511	Updates on Influenza Vaccination in Children. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 75-89.	1.9	22
512	Development of a novel equine influenza virus live-attenuated vaccine. <i>Virology</i> , 2018, 516, 76-85.	1.1	26
513	Influenza vaccines: Evaluation of the safety profile. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 657-670.	1.4	48
514	Does consecutive influenza vaccination reduce protection against influenza: A systematic review and meta-analysis. <i>Vaccine</i> , 2018, 36, 3434-3444.	1.7	29
515	Recombinant Newcastle disease virus (NDV) expressing Duck Tembusu virus (DTMUV) pre-membrane and envelope proteins protects ducks against DTMUV and NDV challenge. <i>Veterinary Microbiology</i> , 2018, 218, 60-69.	0.8	19
516	Activation and Induction of Antigen-Specific T Follicular Helper Cells Play a Critical Role in Live-Attenuated Influenza Vaccine-Induced Human Mucosal Anti-influenza Antibody Response. <i>Journal of Virology</i> , 2018, 92, .	1.5	36
517	Safety of Russian-Backbone Trivalent, Live Attenuated Seasonal Influenza Vaccine in Healthy Subjects: Open-Label, Non-randomized Phase 4 Study. <i>Drug Safety</i> , 2018, 41, 171-177.	1.4	7
518	Perspectives from the Society for Pediatric Research: Decreased Effectiveness of the Live Attenuated Influenza Vaccine. <i>Pediatric Research</i> , 2018, 83, 31-40.	1.1	12
519	Immune responses after live attenuated influenza vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 571-578.	1.4	114
520	Colocalization of intracellular specific IgA (icIgA) with influenza virus in patientsâ€™ nasopharyngeal aspirate cells. <i>Journal of Virological Methods</i> , 2018, 252, 8-14.	1.0	5
521	Influenza burden, prevention, and treatment in asthmaâ€“A scoping review by the <scp>EAACI</scp> Influenza in asthma task force. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1151-1181.	2.7	47
522	How long are children protected by influenza vaccination?. <i>Lancet Respiratory Medicine</i> , the, 2018, 6, 889-891.	5.2	0
523	Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink. <i>BMJ Open</i> , 2018, 8, e023118.	0.8	8

#	ARTICLE	IF	CITATIONS
524	Modulation of Innate Immune Responses by the Influenza A NS1 and PA-X Proteins. <i>Viruses</i> , 2018, 10, 708.	1.5	66
526	The Clinician's Vaccine Safety Resource Guide. , 2018, , .		8
527	Temperature Sensitive Mutations in Influenza A Viral Ribonucleoprotein Complex Responsible for the Attenuation of the Live Attenuated Influenza Vaccine. <i>Viruses</i> , 2018, 10, 560.	1.5	36
528	Generation of a broadly reactive influenza H1 antigen using a consensus HA sequence. <i>Vaccine</i> , 2018, 36, 4837-4845.	1.7	7
529	Technologies to Improve Immunization. , 2018, , 1320-1353.e17.		15
530	Pan-Influenza A Protection by Prime-Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model. <i>Frontiers in Immunology</i> , 2018, 9, 116.	2.2	11
531	Overcoming the Neonatal Limitations of Inducing Germinal Centers through Liposome-Based Adjuvants Including C-Type Lectin Agonists Trehalose Dibehenate or Curdlan. <i>Frontiers in Immunology</i> , 2018, 9, 381.	2.2	43
532	Neonatal Immunization: Rationale, Current State, and Future Prospects. <i>Frontiers in Immunology</i> , 2018, 9, 532.	2.2	40
533	To mist or not to mist: An update on the recommendations for live-attenuated influenza vaccine. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2018, 58, 457-459.	0.7	1
534	Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine. <i>Vaccines</i> , 2018, 6, 18.	2.1	89
535	Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) – United States, 2018–19 Influenza Season. <i>Morbidity and Mortality Weekly Report</i> , 2018, 67, 643-645.	9.0	70
536	Measurement of Vaccine Direct Effects Under the Test-Negative Design. <i>American Journal of Epidemiology</i> , 2018, 187, 2686-2697.	1.6	91
537	Live Attenuated Influenza Vaccine: Is Past Performance a Guarantee of Future Results?. <i>Clinical Therapeutics</i> , 2018, 40, 1246-1254.	1.1	10
538	Incompatible Translation Drives a Convergent Evolution and Viral Attenuation During the Development of Live Attenuated Vaccine. <i>Frontiers in Cellular and Infection Microbiology</i> , 2018, 8, 249.	1.8	13
539	Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine. <i>Journal of Virology</i> , 2018, 92, .	1.5	10
540	Inactivated Influenza Vaccines. , 2018, , 456-488.e21.		14
541	Influenza Vaccine – Live. , 2018, , 489-510.e7.		2
542	Prevention of allergy by virus-like nanoparticles (<sc>VNP</sc>) delivering shielded versions of major allergens in a humanized murine allergy model. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 246-260.	2.7	31

#	ARTICLE	IF	CITATIONS
543	Mucosal Vaccination via the Respiratory Tract. <i>Pharmaceutics</i> , 2019, 11, 375.	2.0	69
544	Comparative Immunogenicity of the 2014â€“2015 Northern Hemisphere Trivalent IIV and LAIV against Influenza A Viruses in Children. <i>Vaccines</i> , 2019, 7, 87.	2.1	7
545	Influenza vaccine programs for children in low- and middle-income countries: current status and way forward. <i>Expert Review of Vaccines</i> , 2019, 18, 711-724.	2.0	5
546	Haemagglutinin stability was not the primary cause of the reduced effectiveness of live attenuated influenza vaccine against A/H1N1pdm09 viruses in the 2013â€“2014 and 2015â€“2016 seasons. <i>Vaccine</i> , 2019, 37, 4543-4550.	1.7	15
547	Evaluation of A(H1N1)pdm09 LAIV vaccine candidates stability and replication efficiency in primary human nasal epithelial cells. <i>Vaccine: X</i> , 2019, 2, 100031.	0.9	10
548	Challenges in the development of egg-independent vaccines for influenza. <i>Expert Review of Vaccines</i> , 2019, 18, 737-750.	2.0	29
549	A Bivalent Live-Attenuated Vaccine for the Prevention of Equine Influenza Virus. <i>Viruses</i> , 2019, 11, 933.	1.5	10
550	Comparative Study of the Temperature Sensitive, Cold Adapted and Attenuated Mutations Present in the Master Donor Viruses of the Two Commercial Human Live Attenuated Influenza Vaccines. <i>Viruses</i> , 2019, 11, 928.	1.5	21
551	Emerging role of T cells in vaccine-mediated protection from infectious diseases. <i>Clinical and Translational Immunology</i> , 2019, 8, e1072.	1.7	18
552	Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV. <i>Vaccines</i> , 2019, 7, 119.	2.1	5
553	Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination. <i>Journal of Clinical Virology</i> , 2019, 119, 44-52.	1.6	107
554	Safety of guidelines recommending live attenuated influenza vaccine for routine use in children and adolescents with asthma. <i>Vaccine</i> , 2019, 37, 4055-4060.	1.7	9
555	Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1. <i>Vaccine</i> , 2019, 37, 3722-3729.	1.7	16
556	Cost-effectiveness of public health interventions against human influenza pandemics in France: a methodological contribution from the FLURESP European Commission project. <i>European Journal of Public Health</i> , 2020, 30, 43-49.	0.1	3
557	Burden, effectiveness and safety of influenza vaccines in elderly, paediatric and pregnant populations. <i>Vaccines</i> , 2019, 7, 251513551982648.	1.4	46
558	Influenza Immunization in Low- and Middle-Income Countries: Preparing for Next-Generation Influenza Vaccines. <i>Journal of Infectious Diseases</i> , 2019, 219, S97-S106.	1.9	43
559	Cross-Protective Abilities of Hyaluronic Acid Modified with Tetraglycine-octaarginine as a Mucosal Adjuvant against Infection with Heterologous Influenza Viruses. <i>Bioconjugate Chemistry</i> , 2019, 30, 3028-3037.	1.8	10
560	The Importance of Vaccinating Children and Pregnant Women against Influenza Virus Infection. <i>Pathogens</i> , 2019, 8, 265.	1.2	8

#	ARTICLE	IF	CITATIONS
561	The efficacy, effectiveness, and immunogenicity of influenza vaccines in Africa: a systematic review. <i>Lancet Infectious Diseases</i> , 2019, 19, e110-e119.	4.6	17
562	Live Attenuated and Inactivated Influenza Vaccine Effectiveness. <i>Pediatrics</i> , 2019, 143, .	1.0	40
563	Development of a Universal Influenza Vaccine. <i>Journal of Immunology</i> , 2019, 202, 392-398.	0.4	83
564	Vaccinating children against influenza increases variability in epidemic size. <i>Epidemics</i> , 2019, 26, 95-103.	1.5	10
565	The use of cell-mediated immunity for the evaluation of influenza vaccines: an upcoming necessity. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1021-1030.	1.4	27
566	Immunogenicity and Viral Shedding of Russian-Backbone, Seasonal, Trivalent, Live, Attenuated Influenza Vaccine in a Phase II, Randomized, Placebo-Controlled Trial Among Preschool-Aged Children in Urban Bangladesh. <i>Clinical Infectious Diseases</i> , 2019, 69, 777-785.	2.9	18
567	The Potential of Live, Attenuated Influenza Vaccine for the Prevention of Influenza in Children. <i>Clinical Infectious Diseases</i> , 2019, 69, 795-796.	2.9	5
568	Future of nanomedicines for treating respiratory diseases. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 59-68.	2.4	19
569	Seasonal Influenza Vaccine Impact on Pandemic H1N1 Vaccine Efficacy. <i>Clinical Infectious Diseases</i> , 2019, 68, 1839-1846.	2.9	3
570	Acute wheeze in the pediatric population: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data. <i>Vaccine</i> , 2019, 37, 392-399.	1.7	2
571	Successes and Failures of the Live-attenuated Influenza Vaccine: Can We Do Better?. <i>Clinical Infectious Diseases</i> , 2020, 70, 1029-1037.	2.9	12
572	Effectiveness of the Live Attenuated Influenza Vaccine: Was the Addition of the Second Type B Lineage a Step Too Far?. <i>Clinical Infectious Diseases</i> , 2020, 70, 2514-2516.	2.9	6
573	Effect of seasonal influenza vaccination on influenza symptom severity among children in Hutterite communities: Follow-up study of a randomized trial. <i>Influenza and Other Respiratory Viruses</i> , 2020, 14, 28-36.	1.5	4
574	Current challenges: from the path of "original antigenic sin" towards the development of universal flu vaccines. <i>International Reviews of Immunology</i> , 2020, 39, 21-36.	1.5	21
575	Why are vaccines against many human viral diseases still unavailable; an historic perspective?. <i>Journal of Medical Virology</i> , 2020, 92, 129-138.	2.5	25
576	Insights into current clinical research on the immunogenicity of live attenuated influenza vaccines. <i>Expert Review of Vaccines</i> , 2020, 19, 43-55.	2.0	11
577	Safety of live attenuated influenza vaccine (LAIV) in children with moderate to severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1157-1164.e6.	1.5	16
578	Understanding Immunity in Children Vaccinated With Live Attenuated Influenza Vaccine. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, S10-S14.	0.6	12

#	ARTICLE	IF	CITATIONS
579	Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAI) Immunogenicity. <i>Vaccines</i> , 2020, 8, 683.	2.1	10
580	Protective Intranasal Immunization Against Influenza Virus in Infant Mice Is Dependent on IL-6. <i>Frontiers in Immunology</i> , 2020, 11, 568978.	2.2	4
581	Routine Childhood Vaccines Given From 1 through 18 Years of Age. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1780-1795.	1.4	0
582	Efficacy and safety of a live attenuated influenza vaccine in Chinese healthy children aged 3-17 years in one study center of a randomized, double-blind, placebo-controlled phase 3 clinical trial, 2016/17 season. <i>Vaccine</i> , 2020, 38, 5979-5986.	1.7	5
583	Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data. <i>Infectious Diseases and Therapy</i> , 2020, 9, 625-639.	1.8	3
584	Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2921-2931.	1.4	85
585	Environmental Lead Exposure and Influenza and Respiratory Syncytial Virus Diagnoses in Young Children: A Test-Negative Case-Control Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 7625.	1.2	2
586	IgA Responses Following Recurrent Influenza Virus Vaccination. <i>Frontiers in Immunology</i> , 2020, 11, 902.	2.2	28
587	History of Live, Attenuated Influenza Vaccine. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, S3-S9.	0.6	3
588	Prospects and Challenges in the Development of Universal Influenza Vaccines. <i>Vaccines</i> , 2020, 8, 361.	2.1	15
589	Signals and trends of Guillain-Barré syndrome after the introduction of live-attenuated vaccines for influenza in the US and South Korean adverse event reporting systems. <i>Vaccine</i> , 2020, 38, 5464-5473.	1.7	5
590	Who and when to vaccinate against influenza. <i>International Journal of Infectious Diseases</i> , 2020, 93, 375-387.	1.5	52
591	The CTA1-DD adjuvant strongly potentiates follicular dendritic cell function and germinal center formation, which results in improved neonatal immunization. <i>Mucosal Immunology</i> , 2020, 13, 545-557.	2.7	15
592	Live Attenuated Cold-Adapted Influenza Vaccines. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 11, a038653.	2.9	9
593	Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model. <i>Antiviral Research</i> , 2020, 178, 104806.	1.9	21
594	Live-attenuated Respiratory Syncytial Virus Vaccines: Time for the Next Step. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 538-539.	2.5	6
595	When Therapeutic IgA Antibodies Might Come of Age. <i>Pharmacology</i> , 2021, 106, 9-19.	0.9	36
596	Influenza in Children. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a038430.	2.9	22



#	ARTICLE	IF	CITATIONS
598	Influenza vaccination: protecting the most vulnerable. <i>European Respiratory Review</i> , 2021, 30, 200258.	3.0	30
600	Effectiveness of Influenza Vaccination in Preventing Hospitalization Due to Influenza in Children: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2021, 73, 1722-1732.	2.9	19
601	Defining the root cause of reduced H1N1 live attenuated influenza vaccine effectiveness: low viral fitness leads to inter-strain competition. <i>Npj Vaccines</i> , 2021, 6, 35.	2.9	13
602	COVID-19 vaccines: The status and perspectives in delivery points of view. <i>Advanced Drug Delivery Reviews</i> , 2021, 170, 1-25.	6.6	262
603	Immune Responses Elicited by Live Attenuated Influenza Vaccines as Correlates of Universal Protection against Influenza Viruses. <i>Vaccines</i> , 2021, 9, 353.	2.1	11
604	In vitro cell culture model of human nasal-associated lymphoid tissue (NALT) to evaluate the humoral immune response to SARS-CoV-2 spike proteins. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 4516-4521.	1.8	6
605	Influenza epidemics. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 350-356.	0.5	1
606	Selecting and Using the Appropriate Influenza Vaccine for Each Individual. <i>Viruses</i> , 2021, 13, 971.	1.5	15
607	Safety of live attenuated influenza vaccine (LAIV) in children and adults with asthma: a systematic literature review and narrative synthesis. <i>Expert Review of Vaccines</i> , 2021, 20, 717-728.	2.0	6
608	OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza. <i>Frontiers in Immunology</i> , 2021, 12, 678483.	2.2	14
609	Progression and Trends in Virus from Influenza A to COVID-19: An Overview of Recent Studies. <i>Viruses</i> , 2021, 13, 1145.	1.5	12
610	A New Master Donor Virus for the Development of Live-Attenuated Influenza B Virus Vaccines. <i>Viruses</i> , 2021, 13, 1278.	1.5	2
611	Evaluation of influenza A and B cold-adapted reassortant virus reproduction in trivalent live influenza vaccines. <i>Virus Research</i> , 2021, 300, 198396.	1.1	3
612	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. <i>Viruses</i> , 2021, 13, 1397.	1.5	6
613	Influenza Viruses: Innate Immunity and mRNA Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 710647.	2.2	22
614	Review of Influenza Virus Vaccines: The Qualitative Nature of Immune Responses to Infection and Vaccination Is a Critical Consideration. <i>Vaccines</i> , 2021, 9, 979.	2.1	13
615	Infection with SARS-CoV-2 primes immunological memory in human nasal-associated lymphoid tissue. <i>Clinical Immunology</i> , 2021, 231, 108850.	1.4	7
616	Use of High-Dose Influenza and Live Attenuated Influenza Vaccines by US Primary Care Physicians. <i>Journal of General Internal Medicine</i> , 2021, 36, 2030-2038.	1.3	1

#	ARTICLE	IF	CITATIONS
618	The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 59-68.	0.9	8
620	Immune Signatures and Systems Biology of Vaccines. , 2011, , 141-167.		2
621	Novel Strategies for Improved Vaccines for the Elderly: The Example of Influenza. , 2012, , 201-227.		2
622	Live Attenuated Influenza Vaccine. , 2011, , 273-291.		2
623	Seasonal Influenza Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2009, 333, 43-82.	0.7	176
624	Live Attenuated Vaccines for Pandemic Influenza. <i>Current Topics in Microbiology and Immunology</i> , 2009, 333, 109-132.	0.7	24
625	Attenuated Influenza Virus Vaccines with Modified NS1 Proteins. <i>Current Topics in Microbiology and Immunology</i> , 2009, 333, 177-195.	0.7	80
626	NHG-Standaard Influenza en influenzavaccinatie. , 2009, , 1314-1332.		5
627	Acute Otitis Media and Otitis Media with Effusion. , 2010, , 2761-2777.		9
628	Influenza Viruses, Including Avian Influenza and Swine Influenza. , 2010, , 2265-2288.		26
630	Influenza Viruses. , 2008, , 1130-1138.		5
632	Influenza Viruses. , 2012, , 1149-1159.e7.		7
633	Microbial otitis media: recent advancements in treatment, current challenges and opportunities. <i>Journal of Medical Microbiology</i> , 2018, 67, 1417-1425.	0.7	21
635	Influenza Vaccines Delivered in Early Childhood Could Turn Antigenic Sin into Antigenic Blessings. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a038471.	2.9	22
636	Vaccine-generated lung tissue-resident memory T cells provide heterosubtypic protection to influenza infection. <i>JCI Insight</i> , 2016, 1, .	2.3	328
637	Influence of Prior Influenza Vaccination on Antibody and B-Cell Responses. <i>PLoS ONE</i> , 2008, 3, e2975.	1.1	208
638	Preclinical Evaluation of a Replication-Deficient Intranasal $\Delta$ NS1 H5N1 Influenza Vaccine. <i>PLoS ONE</i> , 2009, 4, e5984.	1.1	66
639	Safety and Immunogenicity Following Administration of a Live, Attenuated Monovalent 2009 H1N1 Influenza Vaccine to Children and Adults in Two Randomized Controlled Trials. <i>PLoS ONE</i> , 2010, 5, e13755.	1.1	57

#	ARTICLE	IF	CITATIONS
640	Evaluation of Live Attenuated H7N3 and H7N7 Vaccine Viruses for Their Receptor Binding Preferences, Immunogenicity in Ferrets and Cross Reactivity to the Novel H7N9 Virus. PLoS ONE, 2013, 8, e76884.	1.1	21
641	Near-Infrared Laser Adjuvant for Influenza Vaccine. PLoS ONE, 2013, 8, e82899.	1.1	39
642	Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses. PLoS ONE, 2014, 9, e103446.	1.1	9
643	Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity. PLoS ONE, 2015, 10, e0137608.	1.1	24
644	Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59. PLoS ONE, 2017, 12, e0169501.	1.1	16
645	Oral immunization of a non-recombinant Lactococcus lactis surface displaying influenza hemagglutinin 1 (HA1) induces mucosal immunity in mice. PLoS ONE, 2017, 12, e0187718.	1.1	10
646	Adjuvanting influenza hemagglutinin vaccine with a human pulmonary surfactant-mimicking synthetic compound SF-10 induces local and systemic cell-mediated immunity in mice. PLoS ONE, 2018, 13, e0191133.	1.1	10
647	Recommendations on the use of live, attenuated influenza vaccine (FluMist®): supplemental statement on seasonal influenza vaccine for 2011-2012. Canada Communicable Disease Report, 2011, 37, 1-77.	0.6	10
648	Statement on Seasonal Influenza Vaccine for 2012-2013: Appendix I: New Evidence Review for Children 24 to 59 Months of Age. Canada Communicable Disease Report, 2012, 38, 1-55.	0.6	16
649	The role of oseltamivir in the treatment and prevention of influenza in children. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 755-767.	1.5	1
650	Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-2016 Influenza Season. Morbidity and Mortality Weekly Report, 2015, 64, 818-825.	9.0	246
651	Prevention and Control of Seasonal Influenza with Vaccines. MMWR Recommendations and Reports, 2016, 65, 1-54.	26.7	357
652	Requirements of New Vaccines against Novel Influenza Viruses. Tropical Medicine and Health, 2014, 42, S87-S89.	1.0	3
653	Decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines: an observational bias or a technical challenge?. Eurosurveillance, 2016, 21, .	3.9	36
654	Systematic review of fever, febrile convulsions and serious adverse events following administration of inactivated trivalent influenza vaccines in children. Eurosurveillance, 2015, 20, .	3.9	17
655	Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada's Sentinel Physician Surveillance Network, January 2015. Eurosurveillance, 2015, 20, .	3.9	91
656	Attenuated Strains of Salmonella enterica Serovars Typhi and Paratyphi as Live Oral Vaccines Against Enteric Fever. , 2016, , 525-533.		1
657	Vaccination of children with a live-attenuated, intranasal influenza vaccine - analysis and evaluation through a Health Technology Assessment. GMS Health Technology Assessment, 2014, 10, Doc03.	2.2	8

#	ARTICLE	IF	CITATIONS
658	Targeted Vaccine Selection in Influenza Vaccination. Deutsches A&#x0308;rzteblatt International, 2013, 110, 793-8.	0.6	10
659	The current state of H5N1 vaccines and the use of the ferret model for influenza therapeutic and prophylactic development. Journal of Infection in Developing Countries, 2012, 6, 465-469.	0.5	32
660	The Daunting Practicalities of In-Office Pediatric Influenza Vaccination: 2009â€“2010. Pediatric Annals, 2009, 38, 655-660.	0.3	6
661	Taking a â€“PASSâ€™™ on Alternative Immunization Schedules. Pediatric Annals, 2013, 42, 399-406.	0.3	3
662	Elicitation of Broadly Protective Antibodies following Infection with Influenza Viruses Expressing H1N1 Computationally Optimized Broadly Reactive Hemagglutinin Antigens. ImmunoHorizons, 2018, 2, 226-237.	0.8	31
663	Chimeric Vaccines Based on Novel Insect-Specific Flaviviruses. Vaccines, 2021, 9, 1230.	2.1	11
665	The Value of Preventive Medicine: A Look at Vaccine Management. Journal of Managed Care Pharmacy, 2007, 13, 2-22.	2.2	11
666	Influenza and influenza vaccination in children. , 2008, , 95-111.		1
667	Live attenuated influenza vaccine. , 2008, , 203-220.		0
668	Routine Use of Influenza Vaccine. Advances in Experimental Medicine and Biology, 2009, 634, 95-110.	0.8	0
669	MÃƒglichkeiten und Strategien der ImpfprÃƒvention. , 2009, , 139-153.		1
670	INFLUENZA VIRUSES. , 2009, , 2395-2413.		6
671	Influenza Vaccines: The Key to Disease Prevention and Control. Pediatric Annals, 2009, 38, 650-654.	0.3	0
672	The Necessity of Influenza Vaccination in Children. Pediatric Annals, 2010, 39, 490-496.	0.3	1
673	Influenza and Influenza Vaccination in Children. , 2011, , 149-171.		1
674	Influenza Viruses. , 2011, , 1121-1125.e1.		1
675	NHG-Standaard Influenza en influenzavaccinatie. , 2011, , 1129-1147.		0
678	Known Vaccine-Associated Adverse Events. , 2013, , 51-86.		0

#	ARTICLE	IF	CITATIONS
679	Perceived Risks from Live Viral Vaccines. , 2013, , 235-254.		0
680	Neue Arzneimittel 2012. , 2013, , 47-120.		1
681	Autoimmunity, Allergies, and Asthma: A Relationship to Vaccines?. , 2013, , 267-290.		0
682	Universal flu vaccination for children gets underway. Independent Nurse, 2013, 2013, .	0.0	0
684	Live viral vaccines in transplanted patients. Swiss Medical Weekly, 2014, 144, w14005.	0.8	8
686	Barriers to Improved Immunization Rates and Ways to Overcome Them. , 2017, , 199-234.		0
687	Influenza Vaccines. , 2017, , 117-125.		0
688	Letter in response to commentary by Small and Cronin. Vaccine, 2017, 35, 5225.	1.7	0
689	INTERCHANGEABILITY OF VIRAL VACCINES FOR IMMUNIZATION. Voprosy Virusologii, 2017, 62, 197-203.	0.1	1
690	Immunization Update. Journal of Contemporary Pharmacy Practice, 2017, 64, 24-27.	0.2	0
691	Do Vaccines Cause Asthma?. , 2018, , 187-191.		0
693	The cellular and humoral immune response to influenza vaccination is comparable in asthmatic and healthy subjects. Human Vaccines and Immunotherapeutics, 2021, 17, 98-105.	1.4	1
694	Immunological memory as the fundamentals of vaccines. Pakistan Biomedical Journal, 2021, 2, .	0.0	0
695	Influenza vaccination for children with asthma. Canadian Family Physician, 2010, 56, 1137-9.	0.1	3
696	Childhood immunization controversies: what are parents asking?. Ochsner Journal, 2008, 8, 151-6.	0.5	1
697	Economics of influenza vaccine administration timing for children. American Journal of Managed Care, 2010, 16, e75-e85.	0.8	18
699	The correlation between the presence of quorum sensing, toxin-antitoxin system genes and MIC values with ability of biofilm formation in clinical isolates of Pseudomonas aeruginosa. Iranian Journal of Microbiology, 2014, 6, 133-9.	0.8	13
700	Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014-15 influenza season. Morbidity and Mortality Weekly Report, 2014, 63, 691-7.	9.0	223

#	ARTICLE	IF	CITATIONS
702	Progress toward the development of universal influenza vaccines. <i>Missouri Medicine</i> , 2014, 111, 321-5.	0.3	0
703	A century of influenza prevention in St. Louis. <i>Missouri Medicine</i> , 2012, 109, 119-23.	0.3	1
705	Eyedrop vaccination: an immunization route with promises for effective responses to pandemics. <i>Expert Review of Vaccines</i> , 2022, 21, 91-101.	2.0	2
706	Nasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020â€21 season. <i>Italian Journal of Pediatrics</i> , 2021, 47, 225.	1.0	9
707	Safety and Immunogenicity of M2-Deficient, Single Replication, Live Influenza Vaccine (M2SR) in Adults. <i>Vaccines</i> , 2021, 9, 1388.	2.1	5
708	Mechanism on antigen delivery under mucosal vaccination using cell-penetrating peptides immobilized at multiple points on polymeric platforms. <i>International Journal of Pharmaceutics</i> , 2022, 613, 121376.	2.6	3
709	Recent advancements and application of in vitro models for predicting inhalation toxicity in humans. <i>Toxicology in Vitro</i> , 2022, 79, 105299.	1.1	8
711	Influenza vaccines: where we are, where we are going. <i>Current Opinion in Pediatrics</i> , 2022, 34, 119-125.	1.0	10
713	Precision Vaccine Development: Cues From Natural Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 662218.	2.2	11
714	Estimation of Relative Vaccine Effectiveness in Influenza: A Systematic Review of Methodology. <i>Epidemiology</i> , 2022, 33, 334-345.	1.2	10
715	Intranasal delivery of a cDC1 targeted influenza vaccine with poly(I:C) enhances T cell responses and protects against influenza infection. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13128.	1.3	0
716	Sequential Delivery of Live Attenuated Influenza Vaccine and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Ferret Model Can Reduce SARS-CoV-2 Shedding and Does Not Result in Enhanced Lung Pathology. <i>Journal of Infectious Diseases</i> , 2022, 225, 404-412.	1.9	9
717	Influenza and Parainfluenza Viral Infections in Children. <i>Pediatrics in Review</i> , 2014, 35, 217-228.	0.2	8
726	Impact of Therapeutics on Unified Immunity During Allergic Asthma and Respiratory Infections. <i>Frontiers in Allergy</i> , 2022, 3, 852067.	1.2	3
727	Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications. <i>Nano Convergence</i> , 2022, 9, 19.	6.3	12
728	Instructing durable humoral immunity for COVID-19 and other vaccinable diseases. <i>Immunity</i> , 2022, 55, 945-964.	6.6	32
729	Acute Otitis Media and Otitis Media with Effusion. , 2015, , 209-227.e6.		1
730	VII International Symposium on Respiratory Viral Infections. <i>Antiviral Therapy</i> , 2007, 12, 671-693.	0.6	5

#	ARTICLE	IF	CITATIONS
731	Mutation L319Q in the PB1 Polymerase Subunit Improves Attenuation of a Candidate Live-Attenuated Influenza A Virus Vaccine. <i>Microbiology Spectrum</i> , 2022, 10, e0007822.	1.2	4
732	Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials. <i>Vaccine</i> , 2022, 40, 4339-4347.	1.7	1
733	A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice. <i>Journal of Virology</i> , 2022, 96, .	1.5	7
734	How nasal-spray vaccines could change the pandemic. <i>Nature</i> , 2022, 609, 240-242.	13.7	45
735	Optimizing the Live Attenuated Influenza A Vaccine Backbone for High-Risk Patient Groups. <i>Journal of Virology</i> , 2022, 96, .	1.5	3
736	Comparison of vaccination efficacy using live or ultraviolet-inactivated influenza viruses introduced by different routes in a mouse model. <i>PLoS ONE</i> , 2022, 17, e0275722.	1.1	6
737	<i>Influenza Viruses.</i> , 2023, , 1205-1213.e5.		0
738	Do we need nasal vaccines against COVID 19 to suppress the transmission of infections?. <i>Microbial Biotechnology</i> , 2023, 16, 3-14.	2.0	6
739	Developing mucosal vaccines for SARS-CoV-2: What will it take?. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	0
740	Comparison of Levels of Nasal, Salivary, and Plasma Antibody to Severe Acute Respiratory Syndrome Coronavirus 2 During Natural Infection and After Vaccination. <i>Clinical Infectious Diseases</i> , 2023, 76, 1391-1399.	2.9	13
741	Revisiting live attenuated influenza vaccine efficacy among children in developing countries. <i>Vaccine</i> , 2023, , .	1.7	0
742	Intracellular immunoglobulin A (<scp>icIgA</scp>) in protective immunity and vaccines. <i>Scandinavian Journal of Immunology</i> , 2023, 97, .	1.3	0
743	Preclinical developments in the delivery of protein antigens for vaccination. <i>Expert Opinion on Drug Delivery</i> , 2023, 20, 367-384.	2.4	1
744	<i>Influenza Viruses.</i> , 2023, , 1-57.		0
746	<i>Influenza Viruses.</i> , 2023, , 1-57.		0
750	Technologies to Improve Immunization. , 2023, , 1397-1431.e18.		0
751	<i>Influenza Vaccine</i> €”Live. , 2023, , 552-576.e8.		0
755	Immune imprinting and next-generation coronavirus vaccines. <i>Nature Microbiology</i> , 2023, 8, 1971-1985.	5.9	4

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------